睿知中国疾病研究地图
候选清单0

长沙中南大学湘雅

中南大学湘雅医院

Xiangya Hospital

在本站收录的 53 种疾病中,这家医院列在其中 39 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

中南大学湘雅医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma63 篇牵头论文
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma8 篇牵头论文
  3. 肝细胞癌Hepatocellular carcinoma119 篇牵头论文牵头 3 项开放试验
  4. 胃癌Stomach cancer35 篇牵头论文
  5. 肝母细胞瘤Hepatoblastoma5 篇牵头论文
  6. 视网膜母细胞瘤Retinoblastoma2 篇牵头论文
  7. 脊索瘤Chordoma1 篇牵头论文
  8. 骨肉瘤Osteosarcoma15 篇牵头论文
  9. 胃肠道间质瘤Gastrointestinal stromal tumour4 篇牵头论文牵头 1 项开放试验
  10. 神经母细胞瘤Neuroblastoma4 篇牵头论文
  11. 尤文肉瘤Ewing sarcoma1 篇牵头论文
  12. 多发性骨髓瘤Multiple myeloma8 篇牵头论文
  13. B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia4 篇牵头论文
  14. 再生障碍性贫血Aplastic anaemia3 篇牵头论文
  15. 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis1 篇牵头论文
  16. β 地中海贫血Beta thalassaemia1 篇牵头论文
  17. 血友病 AHaemophilia A1 篇牵头论文
  18. 非典型溶血性尿毒症综合征Atypical haemolytic uraemic syndrome0 篇牵头论文
  19. 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura2 篇牵头论文
  20. 范可尼贫血Fanconi anaemia1 篇牵头论文
  21. 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder5 篇牵头论文
  22. IgG4相关性疾病IgG4-related disease1 篇牵头论文
  23. 重症肌无力Myasthenia gravis20 篇牵头论文
  24. 烟雾病Moyamoya disease6 篇牵头论文
  25. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis2 篇牵头论文
  26. 大动脉炎Takayasu arteritis1 篇牵头论文
  27. 特发性肺纤维化Idiopathic pulmonary fibrosis4 篇牵头论文
  28. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis23 篇牵头论文
  29. 脊髓性肌萎缩症Spinal muscular atrophy2 篇牵头论文
  30. 法布雷病Fabry disease0 篇牵头论文
  31. 庞贝病Pompe disease0 篇牵头论文
  32. 杜氏肌营养不良Duchenne muscular dystrophy3 篇牵头论文
  33. 白塞病Behçet disease1 篇牵头论文
  34. Alport 综合征Alport syndrome0 篇牵头论文
  35. IgA 肾病IgA nephropathy4 篇牵头论文
  36. 成骨不全症Osteogenesis imperfecta1 篇牵头论文
  37. 原发性胆汁性胆管炎Primary biliary cholangitis0 篇牵头论文
  38. 原发性硬化性胆管炎Primary sclerosing cholangitis1 篇牵头论文
  39. 家族性腺瘤性息肉病Familial adenomatous polyposis0 篇牵头论文

未列出的收录疾病:肝豆状核变性、胆道闭锁、肝包虫病、肺淋巴管平滑肌瘤病、戈谢病、尼曼-匹克病 C 型、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 63 篇,占 2.6%。

牵头论文
63
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
9
由其他机构牵头
每年牵头的论文数
2021: 131320212022: 141420222023: 8820232024: 111120242025: 15152025

长沙有 5 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下

这家医院参与的开放试验 9

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Individualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal Carcinoma
    分期
    III期
    开始
    2026-07
    登记号
    NCT07661771

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 6 家列出的医院为研究中心东莞、中山、佛山、广州、深圳、长沙

  2. 正在招募
    QL1706(PD-1/CTLA-4 双特异性抗体)联合放化疗用于局部区域晚期鼻咽癌QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
    分期
    III期
    开始
    2025-05
    登记号
    NCT06749899

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 17 家列出的医院为研究中心上海、东莞、中山、佛山、南京、南宁、厦门、天津、广州、成都、武汉、福州、贵阳、长沙

  3. 正在招募
    LDRT and Chemoimmunotherapy in NPC With Liver Metastasis
    分期
    II期
    开始
    2025-01
    登记号
    NCT06788002

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:湖南省肿瘤医院;另有 2 家列出的医院为研究中心长沙

  4. 正在招募
    A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
    分期
    II期
    开始
    2025-04
    登记号
    NCT06839066

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心东莞、中山、南宁、广州、成都、杭州、武汉、深圳、福州、赣州、长沙

  5. 正在招募
    Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
    分期
    II期
    开始
    2025-06
    登记号
    NCT07070479

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心中山、广州、珠海、长沙

  6. 正在招募
    喉咽清口服液防治鼻咽癌放射性口腔黏膜炎Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
    分期
    III期
    开始
    2025-12
    登记号
    NCT07311772

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 16 家列出的医院为研究中心上海、北京、南宁、常州、广州、成都、昆明、杭州、梧州、汕头、珠海、福州、长沙

  7. 正在招募
    Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
    分期
    III期
    开始
    2025-11
    登记号
    NCT07328841

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心中山、南宁、广州、梧州、武汉、汕头、珠海、长沙

  8. 正在招募
    40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
    分期
    III期
    开始
    2025-11
    登记号
    NCT07328854

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心中山、南宁、广州、成都、昆明、杭州、梧州、汕头、珠海、福州、长沙

  9. 正在招募
    Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
    分期
    III期
    开始
    2024-03
    登记号
    NCT06239727

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 21 家列出的医院为研究中心东莞、佛山、南京、南宁、南昌、厦门、天津、广州、成都、杭州、武汉、汕头、海口、湛江、福州、西安、贵阳、重庆、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。卡片标题如有中文,为 AI 生成的译文,英文原文附后。

这些数字背后的记录
研究主题放疗技术复发与转移诱导/同步化疗
论文中的科室肿瘤内科耳鼻喉/头颈外科病理/检验科影像/核医学科

这些论文过半是实验室或动物研究。

牵头的论文63
  1. A11 Peptide Enhances Radiosensitivity by Degrading EphA2 in Nasopharyngeal Carcinoma.2026Cancer science免费全文
  2. A Novel Peculiarity of TXNIP Reversing the Radioresistance of NPC and Inducing Ferroptosis by xCT-GSH-GPX4-ROS Axis.2026Head & neck
  3. Vinburnine Sensitizes Radiotherapy Efficacy in Nasopharyngeal Carcinoma by Triggering Pyroptosis and Immune Responses via Activation of EDAR-NFκB Pathway.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  4. Deacetylation of TALDO1 by HDAC6 promotes glycolysis and nasopharyngeal carcinoma progression through a moonlighting function.2025Cell death & disease免费全文
  5. HAT1/HDAC2 mediated ACSL4 acetylation confers radiosensitivity by inducing ferroptosis in nasopharyngeal carcinoma.2025Cell death & disease免费全文
  6. Targeting EGFR-binding protein SLC7A11 enhancing antitumor immunity of T cells via inducing MHC-I antigen presentation in nasopharyngeal carcinoma.2025Cell death & disease免费全文
  7. Chemoradiotherapy Strategies for Immunotherapy-Sensitive Multi-Metastatic Nasopharyngeal Carcinoma: A Comparative Case Report and Literature Review.2025Current oncology (Toronto, Ont.)免费全文
  8. Chemoradiotherapy plus immunotherapy for locoregionally advanced nasopharyngeal carcinoma: A cost-effectiveness analysis.2025Head & neck
  9. USP5 Binds and Stabilizes EphA2 to Increase Nasopharyngeal Carcinoma Radioresistance.2025International journal of biological sciences免费全文
  10. Ferroptosis inhibition via the ROS-GPX4 axis drives microplastic-induced malignant progression of nasopharyngeal carcinoma.2025Journal of translational medicine免费全文
  11. ANXA1 Binds and Stabilizes EGFR to Promote Nasopharyngeal Carcinoma Radioresistance.2025Molecular cancer therapeutics
  12. HDAC1/2-mediated deacetylation of KLF9 promotes the malignant progression of nasopharyngeal carcinoma via CDH17.2025Oncogene
  13. The dynamic changes of glymphatic function at different post-radiotherapy stages in patients with nasopharyngeal carcinoma.2025Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  14. Multiparameter diagnostic model using S100A9, CCL5 and blood biomarkers for nasopharyngeal carcinoma.2025Scientific reports免费全文
  15. Financial toxicity-related factors in patients with nasopharyngeal carfcinoma: a cross-sectional study.2025Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  16. Malnutrition Indicate Poor Clinical Outcome in Patients With NPC: A Multicenter Cohort Study.2025The Laryngoscope
  17. Classifications of Postradiation Nasopharyngeal Necrosis for Guiding Transnasal Endoscopic Nasopharyngeal Skull Base Surgery.2025The Laryngoscope
  18. CYLD induces high oxidative stress and DNA damage through class I HDACs to promote radiosensitivity in nasopharyngeal carcinoma.2024Cell death & disease免费全文
  19. Amyloid aggregates induced by the p53-R280T mutation lead to loss of p53 function in nasopharyngeal carcinoma.2024Cell death & disease免费全文
  20. HNRNPH1 stabilizes FLOT2 mRNA in a non-canonical m6A-dependent manner to promote malignant progression in nasopharyngeal carcinoma.2024Cellular oncology (Dordrecht, Netherlands)免费全文
  21. Silencing AHNAK promotes nasopharyngeal carcinoma progression by upregulating the ANXA2 protein.2024Cellular oncology (Dordrecht, Netherlands)免费全文
  22. Cost-effectiveness analysis of tislelizumab in combination with chemotherapy for the first-line treatment of patients with metastatic or recurrent nasopharyngeal carcinoma in China.2024Head & neck
  23. ANXA6 expression as a potential indicator of tumor diagnosis, metastasis and immunity in nasopharyngeal carcinoma.2024International journal of biological macromolecules
  24. LncRNA BC200 promotes the development of EBV-associated nasopharyngeal carcinoma by competitively binding to miR-6834-5p to upregulate TYMS expression.2024International journal of biological macromolecules
  25. Suppression of the SLC7A11/glutathione axis causes ferroptosis and apoptosis and alters the mitogen-activated protein kinase pathway in nasopharyngeal carcinoma.2024International journal of biological macromolecules
  26. CT-based peritumoral radiomics nomogram on prediction of response and survival to induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.2024Journal of cancer research and clinical oncology免费全文
  27. Epstein-Barr virus-driven metabolic alterations contribute to the viral lytic reactivation and tumor progression in nasopharyngeal carcinoma.2024Journal of medical virology
  28. Transcriptional pausing induced by ionizing radiation enables the acquisition of radioresistance in nasopharyngeal carcinoma.2024Journal of molecular cell biology免费全文
  29. Amide proton transfer (APT) and magnetization transfer (MT) in predicting short-term therapeutic outcome in nasopharyngeal carcinoma after chemoradiotherapy: a feasibility study of three-dimensional chemical exchange saturation transfer (CE2023Cancer imaging : the official publication of the International Cancer Imaging Society免费全文
  30. HDAC4 mediated LHPP deacetylation enhances its destabilization and promotes the proliferation and metastasis of nasopharyngeal carcinoma.2023Cancer letters
  31. Exosomes loaded with circPARD3 promotes EBV-miR-BART4-induced stemness and cisplatin resistance in nasopharyngeal carcinoma side population cells through the miR-579-3p/SIRT1/SSRP1 axis.2023Cell biology and toxicology
  32. Tumor volume reduction after induction chemotherapy with gemcitabine plus cisplatin in nasopharyngeal carcinoma.2023European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  33. The effects of doxorubicin loaded aptamer S3-linked DNA tetrahedrons on nasopharyngeal carcinoma.2023Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale免费全文
  34. A two-stage genome-wide association study identifies novel germline genetic variations in CACNA2D3 associated with radiotherapy response in nasopharyngeal carcinoma.2023Journal of translational medicine免费全文
  35. Radiosensitization of Nasopharyngeal Carcinoma by Graphene Oxide Nanosheets to Reduce Bcl-2 Level.2023Langmuir : the ACS journal of surfaces and colloids
  36. Proteomics Profiling Reveals the Molecular Signatures and Potential Therapeutic Targets of Human Nasopharyngeal Carcinoma.2023Molecular & cellular proteomics : MCP免费全文
  37. CPT1A-mediated fatty acid oxidation promotes cell proliferation via nucleoside metabolism in nasopharyngeal carcinoma.2022Cell death & disease免费全文
  38. MFSD4A inhibits the malignant progression of nasopharyngeal carcinoma by targeting EPHA2.2022Cell death & disease免费全文
  39. CircTMTC1 contributes to nasopharyngeal carcinoma progression through targeting miR-495-MET-eIF4G1 translational regulation axis.2022Cell death & disease免费全文
  40. Salvage Endoscopic Skull Base Surgery: Another Treatment Option After Immunotherapy for Recurrent Nasopharyngeal Carcinoma.2022Frontiers in immunology免费全文
  41. Radiosensitizer EXO-miR-197-3p Inhibits Nasopharyngeal Carcinoma Progression and Radioresistance by Regulating the AKT/mTOR Axis and HSPA5-mediated Autophagy.2022International journal of biological sciences免费全文
  42. TBL1X and Flot2 form a positive feedback loop to promote metastasis in nasopharyngeal carcinoma.2022International journal of biological sciences免费全文
  43. PGC1α-mediated fatty acid oxidation promotes TGFβ1-induced epithelial-mesenchymal transition and metastasis of nasopharyngeal carcinoma.2022Life sciences
  44. A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma.2022Molecular cancer免费全文
  45. Efficacy of chemoradiotherapy in survival of stage Ⅳ nasopharyngeal carcinoma and establishment of a prognostic model.2022Oral oncology
  46. Pathogenesis and Diagnostic Significance of EBV-miR-BARTs in Nasopharyngeal Carcinoma.2022Oxidative medicine and cellular longevity免费全文
  47. Nomogram for distant metastasis-free survival in patients with locoregionally advanced nasopharyngeal carcinoma.2022Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
  48. Neutrophil-to-lymphocyte ratio trend: A novel prognostic predictor in patients with nasopharyngeal carcinoma receiving radiotherapy.2022The International journal of biological markers
  49. Gemcitabine Versus Docetaxel Plus Cisplatin as Induction Chemotherapy in Nasopharyngeal Carcinoma.2022The Laryngoscope
  50. CapG promoted nasopharyngeal carcinoma cell motility involving Rho motility pathway independent of ROCK.2022World journal of surgical oncology免费全文
  51. Flotillin-2 promotes cell proliferation via activating the c-Myc/BCAT1 axis by suppressing miR-33b-5p in nasopharyngeal carcinoma.2021Aging免费全文
  52. The efficacy of locoregional radiotherapy plus chemotherapy vs. chemotherapy alone in metastatic nasopharyngeal carcinoma: a meta-analysis.2021Annals of palliative medicine
  53. Curcumol inhibits EBV-positive Nasopharyngeal carcinoma migration and invasion by targeting nucleolin.2021Biochemical pharmacology
  54. EBV-LMP1 promotes radioresistance by inducing protective autophagy through BNIP3 in nasopharyngeal carcinoma.2021Cell death & disease免费全文
  55. LncRNA linc00312 suppresses radiotherapy resistance by targeting DNA-PKcs and impairing DNA damage repair in nasopharyngeal carcinoma.2021Cell death & disease免费全文
  56. The change in tumor volume after induction chemotherapy with docetaxel plus cisplatin in 259 nasopharyngeal carcinoma patients.2021European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  57. Magnetic resonance imaging-based radiogenomics analysis for predicting prognosis and gene expression profile in advanced nasopharyngeal carcinoma.2021Head & neck
  58. Reply: Diagnostic value of exosomal circMYC in radioresistant nasopharyngeal carcinoma: Methodological issues.2021Head & neck
  59. The role of Exosomes in the Pathogenesis of Nasopharyngeal Carcinoma and the involved Clinical Application.2021International journal of biological sciences免费全文
  60. Brain-Specific Relative Biological Effectiveness of Protons Based on Long-term Outcome of Patients With Nasopharyngeal Carcinoma.2021International journal of radiation oncology, biology, physics
  61. Galectin‑3 facilitates the proliferation and migration of nasopharyngeal carcinoma cells via activation of the ERK1/2 and Akt signaling pathways, and is positively correlated with the inflammatory state of nasopharyngeal carcinoma.2021Molecular medicine reports免费全文
  62. CircRNA circTRAF3 promotes nasopharyngeal carcinoma metastasis through targeting miR-203a-3p/AKT3 axis.2021Pathology, research and practice
  63. Paradoxical effects of DNA tumor virus oncogenes on epithelium-derived tumor cell fate during tumor progression and chemotherapy response.2021Signal transduction and targeted therapy免费全文
中文论文(未计入)3
  1. Causes of missed MRI diagnosis of radiotherapy-induced temporal lobe injury in nasopharyngeal carcinoma.2024Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences免费全文
  2. [Application of temporalis muscle flap in repair and reconstruction after the resection of tumor or necrotic foci following radiotherapy of nasopharyngeal carcinoma].2022Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  3. [Clinical study on endoscopic surgery for soft tissue necrosis of cranial base after radiotherapy for nasopharyngeal carcinoma].2021Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)18
  1. Development of Intelligent Model for Radioactive Brain Damage of Nasopharyngeal Carcinoma Based on Radio-metabolomics状态不明NCT05547971牵头方2022-09 启动
  2. Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma已完成NCT01449942牵头方I/II期2009-05 启动
  3. Individualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal Carcinoma正在招募NCT07661771研究中心III期2026-07 启动
  4. Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid正在招募NCT07311772研究中心III期2025-12 启动
  5. Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy正在招募NCT07328841研究中心III期2025-11 启动
  6. Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial正在招募NCT07070479研究中心II期2025-06 启动
  7. QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.正在招募NCT06749899研究中心III期2025-05 启动
  8. 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma正在招募NCT07328854研究中心III期2025-11 启动
  9. A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy正在招募NCT06839066研究中心II期2025-04 启动
  10. LDRT and Chemoimmunotherapy in NPC With Liver Metastasis正在招募NCT06788002研究中心II期2025-01 启动
  11. Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response正在招募NCT06239727研究中心III期2024-03 启动
  12. Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)进行中,不再招募NCT05587374研究中心III期2023-08 启动
  13. TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma已完成NCT05563480研究中心II期2022-10 启动
  14. Development and Validation of a Deep Learning System for Nasopharyngeal Carcinoma Using Endoscopic Images状态不明NCT05627310研究中心2022-11 启动
  15. PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma进行中,不再招募NCT04907370研究中心III期2021-08 启动
  16. Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma已完成NCT03984357研究中心II期2020-03 启动
  17. PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma状态不明NCT03427827研究中心III期2018-07 启动
  18. Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma状态不明NCT03700476研究中心III期2018-12 启动
PubMed 以外找到的论文(未计入)49
  1. 1371P Nivolumab plus chemoradiotherapy sparing concurrent cisplatin in nasopharyngeal carcinoma (NPC): Social reintegration and patient-reported outcomes (PROs) in quality-of-life (QoL) and tolerability from a phase II PLATINUM trial2025Annals of Oncology论文
  2. Bionic nanobombs target nasopharyngeal carcinoma to enhance the efficacy of chemoradiotherapy by destroying DNA damage repair systems2025Open Research (University of Surrey)论文
  3. CircARHGAP12 suppresses cisplatin-induced alkaliptosis in nasopharyngeal carcinoma through G3BP1-mediated upregulation of CA9 in an RNA G-quadruplex-dependent manner2025Research Square预印本
  4. Combination of Tim-3 blockade TQB2618 with penpulimab and chemotherapy in the first-line treatment of recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): A multicenter, single-arm, two-cohort, phase 2 study.2025Journal of Clinical Oncology会议摘要
  5. Optimization of the 9th Ajcc/Uicc Tnm Staging System for Nasopharyngeal Carcinoma Based on Age and Pretreatment Ebv DNA: Exploring Prognostic Stratification and Individualized Treatment Strategies for Stage Ii-Iii Patients2025SSRN Electronic Journal预印本
  6. PD-1 blockade with toripalimab incorporated into induction chemotherapy and radiotherapy with or without concurrent cisplatin in locoregionally advanced nasopharyngeal carcinoma (DIAMOND): A multicenter, non-inferiority, phase 3, randomized2025Journal of Clinical Oncology论文
  7. 153P Combination of Tim-3 blockade TQB2618 with PD-1 blockade for patients with immunotherapy-resistant recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): Preliminary results from a phase II study2024Immuno-Oncology Technology论文
  8. Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial.2024Journal of Clinical Oncology会议摘要
  9. Analysis of proliferating Treg cells as a predictor for immunotherapy response using systemic longitudinal immune profiling: Biomarker analysis of the phase 3 CONTINUUM trial.2024Journal of Clinical Oncology会议摘要
  10. Nivolumab combined with chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): A multicenter, single-arm, phase II clinical trial.2024Journal of Clinical Oncology会议摘要
  11. Nivolumab combined with radical chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): An investigator-initiated, open-label, multicenter, single-arm, phase II clinical trial2024Journal of Clinical Oncology会议摘要
  12. PD-1 blockade with camrelizumab after chemoradiotherapy in nasopharyngeal carcinoma.2024Journal of Clinical Oncology会议摘要
  13. Prognostic analysis of nimotuzumab combined with concurrent chemoradiotherapy in locally advanced cervical cancer: A multicenter real-world study.2024Journal of Clinical Oncology会议摘要
  14. RETRACTED: METTL14 Promotes Lipid Metabolism Reprogramming and Sustains Nasopharyngeal Carcinoma Progression via Enhancing m6A Modification of ANKRD22 mRNA2024Research Square预印本
  15. SPP1+ tumor-associated macrophages induce radioresistance of nasopharyngeal carcinoma through crosstalk with the tumor microenvironment2024bioRxiv (Cold Spring Harbor Laboratory)预印本
  16. CACA guidelines for holistic integrative management of nasopharyngeal carcinoma2023Holistic Integrative Oncology论文
  17. Data from Epstein–Barr Virus–Encoded Circular RNA CircBART2.2 Promotes Immune Escape of Nasopharyngeal Carcinoma by Regulating PD-L12023未列出期刊其他
  18. PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM)2023Journal of Clinical Oncology会议摘要
  19. Additional file 1 of A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma2022Figshare数据集
  20. Additional file 1 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  21. Additional file 11 of Splicing factor derived circular RNA circCAMSAP1 accelerates nasopharyngeal carcinoma tumorigenesis via a SERPINH1/c-Myc positive feedback loop2022Figshare数据集
  22. Additional file 12 of Splicing factor derived circular RNA circCAMSAP1 accelerates nasopharyngeal carcinoma tumorigenesis via a SERPINH1/c-Myc positive feedback loop2022Figshare数据集
  23. Additional file 13 of Splicing factor derived circular RNA circCAMSAP1 accelerates nasopharyngeal carcinoma tumorigenesis via a SERPINH1/c-Myc positive feedback loop2022Figshare数据集
  24. Additional file 14 of Splicing factor derived circular RNA circCAMSAP1 accelerates nasopharyngeal carcinoma tumorigenesis via a SERPINH1/c-Myc positive feedback loop2022Figshare数据集
  25. Additional file 15 of Splicing factor derived circular RNA circCAMSAP1 accelerates nasopharyngeal carcinoma tumorigenesis via a SERPINH1/c-Myc positive feedback loop2022Figshare数据集
  26. Additional file 16 of Splicing factor derived circular RNA circCAMSAP1 accelerates nasopharyngeal carcinoma tumorigenesis via a SERPINH1/c-Myc positive feedback loop2022Figshare数据集
  27. Additional file 17 of Splicing factor derived circular RNA circCAMSAP1 accelerates nasopharyngeal carcinoma tumorigenesis via a SERPINH1/c-Myc positive feedback loop2022Figshare数据集
  28. Additional file 2 of CapG promoted nasopharyngeal carcinoma cell motility involving Rho motility pathway independent of ROCK2022Figshare数据集
  29. Additional file 2 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  30. Additional file 2 of Splicing factor derived circular RNA circCAMSAP1 accelerates nasopharyngeal carcinoma tumorigenesis via a SERPINH1/c-Myc positive feedback loop2022Figshare数据集
  31. Additional file 3 of CapG promoted nasopharyngeal carcinoma cell motility involving Rho motility pathway independent of ROCK2022Figshare数据集
  32. Additional file 3 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  33. Additional file 4 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  34. Additional file 4 of Splicing factor derived circular RNA circCAMSAP1 accelerates nasopharyngeal carcinoma tumorigenesis via a SERPINH1/c-Myc positive feedback loop2022Figshare数据集
  35. Additional file 5 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  36. Additional file 6 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  37. Additional file 7 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  38. Additional file 8 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  39. Additional file 9 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  40. Fabrication of metformin and survivin siRNA encapsulated into polyethyleneimine-altered silk fibroin nanoparticles for the treatment of nasopharyngeal carcinoma2022Process Biochemistry论文
  41. Functional Characterization of p53 in NPC C666-1 Cells by CRISPR-Based Gene Knockout and Transcriptome Sequencing2022SSRN Electronic Journal预印本
  42. 909P A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy: Updated results2021Annals of Oncology论文
  43. Additional file 1 of Circular RNA circRNF13 inhibits proliferation and metastasis of nasopharyngeal carcinoma via SUMO22021Figshare数据集
  44. Additional file 2 of Circular RNA circRNF13 inhibits proliferation and metastasis of nasopharyngeal carcinoma via SUMO22021Figshare数据集
  45. Camrelizumab versus placebo combined with gemcitabine and cisplatin for recurrent or metastatic nasopharyngeal carcinoma: A randomized, double-blind, phase 3 trial.2021Journal of Clinical Oncology会议摘要
  46. Elevated transcriptional pausing of RNA polymerase II underlies acquired resistance to radiotherapy2021bioRxiv (Cold Spring Harbor Laboratory)预印本
  47. Long intergenic non-protein coding RNA 02570 promotes nasopharyngeal carcinoma progression by adsorbing microRNA miR-4649-3p thereby upregulating both sterol regulatory element binding protein 1, and fatty acid synthase2021Figshare数据集
  48. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial.2021Journal of Clinical Oncology会议摘要
  49. [Retracted] MicroRNA‑214 promotes proliferation and inhibits apoptosis via targeting Bax in nasopharyngeal carcinoma cells2021Molecular Medicine Reports论文

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 8 篇,占 0.3%。

牵头论文
8
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 2220222023: 0020232024: 2220242025: 222025

长沙有 3 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。

这些数字背后的记录
研究主题分子标志物与基因手术新辅助与综合治疗
论文中的科室肿瘤内科病理/检验科消化/肝病科

这些论文过半是实验室或动物研究。

牵头的论文8
  1. Shared chemoresistance genes in ESCC and cervical Cancer: Insights from pharmacogenomics and Mendelian randomization.2025International immunopharmacology
  2. MTHFD2 promotes esophageal squamous cell carcinoma progression via m6A modification‑mediated upregulation and modulation of the PEBP1‑RAF1 interaction.2025International journal of molecular medicine免费全文
  3. Prognostic and clinical significance of tumor-associated macrophages in esophageal squamous cell carcinoma after surgery: do biomarkers and distributions matter?2024Bioscience reports免费全文
  4. Classification and prediction of chemoradiotherapy response and survival from esophageal carcinoma histopathology images.2024Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
  5. Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis.2022Advances in therapy
  6. OPN Promotes Cell Proliferation and Invasion through NF-κB in Human Esophageal Squamous Cell Carcinoma.2022Genetics research免费全文
  7. Reduced LINC00551 expression promotes proliferation and invasion of esophageal squamous cancer by increase in HSP27 phosphorylation.2021Journal of cellular physiology
  8. Silencing of UAP1L1 inhibits proliferation and induces apoptosis in esophageal squamous cell carcinoma.2021Molecular carcinogenesis
中文论文(未计入)1
  1. [Clinical and prognostic features of the patients with esophageal squamous cell carcinomas as a first primary malignancy].2021Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.已完成NCT05142709研究中心2021-10 启动
PubMed 以外找到的论文(未计入)7
  1. PT2.10.03 Safety, Tolerability and Preliminary Efficacy of Anti-PD-L1 ADC HLX43 in Advanced/Metastatic Solid Tumors: A Phase I Study2025Journal of Thoracic Oncology论文
  2. Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma2022Figshare数据集
  3. Additional file 2 of Serum proteomics unveil characteristic protein diagnostic biomarkers and signaling pathways in patients with esophageal squamous cell carcinoma2022Figshare数据集
  4. Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study2021Research Square预印本
  5. Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study2021Research Square预印本
  6. MicroRNA-624-mediated ARRDC3/YAP/HIF1α axis enhances esophageal squamous cell carcinoma cell resistance to cisplatin and paclitaxel2021Figshare数据集
  7. Radiotherapy for Esophageal Squamous Cell Carcinoma Concomitant With Hypoproteinemia: a Case Report2021未列出期刊预印本

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 119 篇,占 0.8%。

牵头论文
119
2021–2025 年
牵头试验
6
任何状态,ClinicalTrials.gov
牵头的开放试验
3
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 262620212022: 353520222023: 232320232024: 151520242025: 19192025

长沙有 6 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 4

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Study on the Treatment of Hepatitis B Virus(HBV) Infected Individuals With Peginterferon α-2b Combined With NA.
    分期
    未注明
    开始
    2023-05
    登记号
    NCT06746701

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中南大学湘雅医院;另有 1 家列出的医院为研究中心广州、长沙

  2. 正在招募
    Antiviral Therapy for Patients With Liver Cancer After Surgery
    分期
    未注明
    开始
    2021-12
    登记号
    NCT05466565

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中南大学湘雅医院长沙

  3. 邀请入组
    JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study
    分期
    I期
    开始
    2025-07
    登记号
    NCT06882876

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:中南大学湘雅医院长沙

  4. 正在招募
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    分期
    III期
    开始
    2023-05
    登记号
    NCT05862337

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 43 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南充、南宁、南昌、南通、台州、合肥、天津、宁波、常州、广州、成都、杭州、沈阳、泸州、济南、海口、温州、福州、蚌埠、西安、郑州、重庆、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后免疫与靶向药物影像、人工智能与早期发现
论文中的科室普外/肝胆胰外科肿瘤内科病理/检验科影像/核医学科

这些论文过半是实验室或动物研究。

牵头的论文119
  1. Quantitative Assessment of Peritumoral Stiffness Using Shell Elastography Enhances the Differentiation of Hepatocellular Carcinoma From Metastatic Liver Carcinoma.2026Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  2. Integrative Multi-Omics Approaches Reveal Selectivity Profiles and Molecular Mechanisms of FIIN-2, a Covalent FGFR Inhibitor.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  3. Gamma-glutamyltransferase and the survival of hepatocellular carcinoma patients after transarterial chemoembolization: a meta‑analysis and systematic review.2025BMC gastroenterology免费全文
  4. Primary liver cancer disease burden in Cambodia during 1990-2021: a systematic analysis of datasets from the global burden of disease study 2021.2025BMC gastroenterology免费全文
  5. Tremelimumab plus durvalumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: a cost-effectiveness analysis from the US payer perspective.2025BMJ open免费全文
  6. The deubiquitinating enzyme ATXN3 promotes hepatocellular carcinoma progression by stabilizing TAZ.2025Cancer gene therapy
  7. CSF3R-AS promotes hepatocellular carcinoma progression and sorafenib resistance through the CSF3R/JAK2/STAT3 positive feedback loop.2025Cell death & disease免费全文
  8. SLC7A11, a disulfidptosis-related gene, correlates with multi-omics prognostic analysis in hepatocellular carcinoma.2025European journal of medical research免费全文
  9. A Novel Signature Composed of Hypoxia, Glycolysis, Lactylation Related Genes to Predict Prognosis and Immunotherapy in Hepatocellular Carcinoma.2025Frontiers in bioscience (Landmark edition)
  10. Deubiquitylating Enzymes in Hepatocellular Carcinoma.2025International journal of biological sciences免费全文
  11. Microwave ablation versus radiofrequency ablation for hepatocellular carcinoma: a propensity score matching and inverse probability weighting analysis.2025International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  12. LncRNA FTX accelerates the progression of hepatocellular carcinoma by FTX/miR-374a-3p/HMGB1 pathway.2025International journal of medical sciences免费全文
  13. CDC5L binds to ELAVL1 to inhibit pyroptosis in hepatocellular carcinoma through the Caspase 3/GSDME signaling pathway.2025International journal of molecular medicine免费全文
  14. USP2-mediated PPARγ stabilization promotes hepatocellular carcinoma progression and M2 macrophage polarization via oleic acid.2025Journal for immunotherapy of cancer免费全文
  15. Transfer learning radiomic model predicts intratumoral tertiary lymphoid structures in hepatocellular carcinoma: a multicenter study.2025Journal for immunotherapy of cancer免费全文
  16. MRI Tomoelastography to Assess the Combined Status of Vessels Encapsulating Tumor Clusters and Microvascular Invasion in Hepatocellular Carcinoma.2025Journal of magnetic resonance imaging : JMRI
  17. The impact of de novo lipogenesis on predicting survival and clinical therapy: an exploration based on a multigene prognostic model in hepatocellular carcinoma.2025Journal of translational medicine免费全文
  18. Comprehensive analysis reveals the prognostic and immunological role of PSMD13 in hepatocellular carcinoma.2025Mammalian genome : official journal of the International Mammalian Genome Society免费全文
  19. The molecular characteristics of DNA damage and repair related to P53 mutation for predicting the recurrence and immunotherapy response in hepatocellular carcinoma.2025Scientific reports免费全文
  20. Long noncoding RNA semaphorin 6A-antisense RNA 1 reduces hepatocellular carcinoma by promoting semaphorin 6A mRNA degradation.2025World journal of gastroenterology免费全文
  21. BRCC36 Deubiquitinates HMGCR to Regulate the Interplay Between Ferroptosis and Pyroptosis.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  22. CD36-mediated accumulation of MDSCs exerts abscopal immunosuppressive responses in hepatocellular carcinoma after insufficient microwave ablation.2024Biochimica et biophysica acta. Molecular basis of disease
  23. Arvanil induces ferroptosis of hepatocellular carcinoma by binding to MICU1.2024Cancer gene therapy
  24. A Novel Amino Acid-Related Gene Signature Predicts Overall Survival in Patients With Hepatocellular Carcinoma.2024Cancer reports (Hoboken, N.J.)免费全文
  25. The survival prediction analysis and preliminary study of the biological function of YEATS2 in hepatocellular carcinoma.2024Cellular oncology (Dordrecht, Netherlands)免费全文
  26. ARL8B promotes hepatocellular carcinoma progression and inhibits antitumor activity of lenvatinib via MAPK/ERK signaling by interacting with RAB2A.2024Cellular signalling
  27. Efficacy and safety comparison between Lenvatinib and Sorafenib in hepatocellular carcinoma treatment: a systematic review and meta-analysis of real-world study.2024European journal of gastroenterology & hepatology免费全文
  28. Design, synthesis, and biological evaluation of selective covalent inhibitors of FGFR4.2024European journal of medicinal chemistry
  29. UCHL3 inhibits ferroptosis by stabilizing β-catenin and maintains stem-like properties of hepatocellular carcinoma cells.2024Free radical biology & medicine
  30. Comprehensive molecular classification predicted microenvironment profiles and therapy response for HCC.2024Hepatology (Baltimore, Md.)免费全文
  31. Is lenvatinib in combination with transarterial chemoembolization benefit for unresectable hepatocellular carcinoma (uHCC)? The age interference needs to be eliminated.2024Hepatology international
  32. Spatial patterns and MRI-based radiomic prediction of high peritumoral tertiary lymphoid structure density in hepatocellular carcinoma: a multicenter study.2024Journal for immunotherapy of cancer免费全文
  33. Deep learning based automatic internal gross target volume delineation from 4D-CT of hepatocellular carcinoma patients.2024Journal of applied clinical medical physics免费全文
  34. The comprehensive roles of lncRNA FAM99A/FAM99B in hepatocellular carcinoma: Expressions, regulatory mechanisms and functional pathway analysis.2024Life sciences
  35. A novel CD8+ T cell-related gene signature as a prognostic biomarker in hepatocellular carcinoma.2024Medicine免费全文
  36. Targeting USP8 Inhibits O-GlcNAcylation of SLC7A11 to Promote Ferroptosis of Hepatocellular Carcinoma via Stabilization of OGT.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  37. Development of tryptophan metabolism patterns to predict prognosis and immunotherapeutic responses in hepatocellular carcinoma.2023Aging免费全文
  38. miR-195-5p Targets CDK1 To Regulate New DNA Synthesis and Inhibit the Proliferation of Hepatocellular Carcinoma Cells.2023Applied biochemistry and biotechnology
  39. Tumor-stroma ratio predicts prognosis and PD-L1 expression in hepatocellular carcinoma.2023BMC cancer免费全文
  40. Targeting of Annexin A1 in Tumor-associated Macrophages as a therapeutic strategy for hepatocellular carcinoma.2023Biochemical pharmacology
  41. Identification of a prognostic cuproptosis-related signature in hepatocellular carcinoma.2023Biology direct免费全文
  42. Acyl-CoA thioesterase 12 suppresses YAP-mediated hepatocarcinogenesis by limiting glycerolipid biosynthesis.2023Cancer letters
  43. Identification of Ferroptosis-related molecular model and immune subtypes of hepatocellular carcinoma for individual therapy.2023Cancer medicine免费全文
  44. Cost-effectiveness analysis of sintilimab plus IBI305 versus sorafenib for unresectable hepatic cell carcinoma in China.2023Cancer medicine免费全文
  45. Competing risk model for prognostic comparison between clear cell type and common type hepatocellular carcinoma: A population-based propensity score matching study.2023Cancer medicine免费全文
  46. Hepatic stellate cell-released CXCL1 aggravates HCC malignant behaviors through the MIR4435-2HG/miR-506-3p/TGFB1 axis.2023Cancer science免费全文
  47. The deubiquitinase EIF3H promotes hepatocellular carcinoma progression by stabilizing OGT and inhibiting ferroptosis.2023Cell communication and signaling : CCS免费全文
  48. Hepatocellular carcinoma cells remodel the pro-metastatic tumour microenvironment through recruitment and activation of fibroblasts via paracrine Egfl7 signaling.2023Cell communication and signaling : CCS免费全文
  49. Sorcin regulate pyroptosis by interacting with NLRP3 inflammasomes to facilitate the progression of hepatocellular carcinoma.2023Cell death & disease免费全文
  50. USP8 positively regulates hepatocellular carcinoma tumorigenesis and confers ferroptosis resistance through β-catenin stabilization.2023Cell death & disease免费全文
  51. RNF2 inhibits E-Cadherin transcription to promote hepatocellular carcinoma metastasis via inducing histone mono-ubiquitination.2023Cell death & disease免费全文
  52. A Phase 1/2 Multicenter Randomized Trial of Local Ablation plus Toripalimab versus Toripalimab Alone for Previously Treated Unresectable Hepatocellular Carcinoma.2023Clinical cancer research : an official journal of the American Association for Cancer ResearchRCT
  53. Lipophagy-related gene RAB7A is involved in immune regulation and malignant progression in hepatocellular carcinoma.2023Computers in biology and medicine
  54. WTAP-mediated m6A modification on circCMTM3 inhibits hepatocellular carcinoma ferroptosis by recruiting IGF2BP1 to increase PARK7 stability.2023Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  55. Circ_0003747 promotes thyroid cancer progression by sponging miR-338-3p to upregulate PLCD3 expression.2023Epigenetics免费全文
  56. The Hepatic Nerves Regulated Inflammatory Effect in the Process of Liver Injury: Is Nerve the Key Treating Target for Liver Inflammation?2023Inflammation
  57. Evaluation of the efficacy and safety of CalliSpheres® microsphere-transarterial chemoembolization in large hepatocellular carcinoma.2023Journal of cancer research and therapeutics
  58. DNA methylation-mediated silencing of Neuronatin promotes hepatocellular carcinoma proliferation through the PI3K-Akt signaling pathway.2023Life sciences
  59. Noninvasive Visualization of Sub-5 mm Orthotopic Hepatic Tumors by a Nanoprobe-Mediated Positive and Reverse Contrast-Balanced Imaging Strategy.2022ACS nano
  60. Identification of ACSF gene family as therapeutic targets and immune-associated biomarkers in hepatocellular carcinoma.2022Aging免费全文
  61. The comprehensive expression and functional analysis of m6A modification "readers" in hepatocellular carcinoma.2022Aging免费全文
  62. The bioinformatics and experimental analysis of the novel roles of virus infection-associated gene CDC20 for prognosis and immune infiltration in hepatocellular carcinoma.2022Aging免费全文
  63. Clinical utility of serum fucosylated fraction of alpha-fetoprotein in the diagnostic of hepatocellular carcinoma: a comprehensive analysis with large sample size.2022Aging免费全文
  64. A comprehensive analysis of FOX family in HCC and experimental evidence to support the oncogenic role of FOXH1.2022Aging免费全文
  65. Integrative bioinformatics and experimental analysis revealed TEAD as novel prognostic target for hepatocellular carcinoma and its roles in ferroptosis regulation.2022Aging免费全文
  66. An M0 macrophage-related prognostic model for hepatocellular carcinoma.2022BMC cancer免费全文
  67. Prognostic Values of BolA Family Member Expression in Hepatocellular Carcinoma.2022BioMed research international免费全文
  68. LncRNA FIRRE promotes the proliferation and metastasis of hepatocellular carcinoma by regulating the expression of PXN through interacting with MBNL3.2022Biochemical and biophysical research communications
  69. The Protein Kinase Activity of NME7 Activates Wnt/β-Catenin Signaling to Promote One-Carbon Metabolism in Hepatocellular Carcinoma.2022Cancer research
  70. Sevoflurane Inhibits Metastasis in Hepatocellular Carcinoma by Inhibiting MiR-665-Induced Activation of the ERK/MMP Pathway.2022Cell transplantation免费全文
  71. Exosomal microRNA-25 released from cancer cells targets SIK1 to promote hepatocellular carcinoma tumorigenesis.2022Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  72. Hydroxysteroid 17-Beta Dehydrogenase 6 Is a Prognostic Biomarker and Correlates with Immune Infiltrates in Hepatocellular Carcinoma.2022Digestive diseases and sciences免费全文
  73. G Protein-Coupled Receptor Kinase 4 Is a Novel Prognostic Factor in Hepatocellular Carcinoma.2022Disease markers免费全文
  74. Single-Cell RNA-seq Analysis Reveals Dysregulated Cell-Cell Interactions in a Tumor Microenvironment Related to HCC Development.2022Disease markers免费全文
  75. The Dysregulation of SOX Family Correlates with DNA Methylation and Immune Microenvironment Characteristics to Predict Prognosis in Hepatocellular Carcinoma.2022Disease markers免费全文
  76. Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma: A network meta-analysis and cost-effectiveness analysis.2022Frontiers in immunology免费全文
  77. Systematic pan-cancer analysis identifies RALA as a tumor targeting immune therapeutic and prognostic marker.2022Frontiers in immunology免费全文
  78. Identification and validation of a tyrosine metabolism-related prognostic prediction model and characterization of the tumor microenvironment infiltration in hepatocellular carcinoma.2022Frontiers in immunology免费全文
  79. Prognostic stratification based on m5C regulators acts as a novel biomarker for immunotherapy in hepatocellular carcinoma.2022Frontiers in immunology免费全文
  80. Activation of VIPR1 suppresses hepatocellular carcinoma progression by regulating arginine and pyrimidine metabolism.2022International journal of biological sciences免费全文
  81. New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials.2022International journal of biological sciences免费全文
  82. Pantothenate Kinase 1 Inhibits the Progression of Hepatocellular Carcinoma by Negatively Regulating Wnt/β-catenin Signaling.2022International journal of biological sciences免费全文
  83. Tryptophan-sorbitol based carbon quantum dots for theranostics against hepatocellular carcinoma.2022Journal of nanobiotechnology免费全文
  84. VCP interaction with HMGB1 promotes hepatocellular carcinoma progression by activating the PI3K/AKT/mTOR pathway.2022Journal of translational medicine免费全文
  85. Circular RNA circ_GLIS2 suppresses hepatocellular carcinoma growth and metastasis.2022Liver international : official journal of the International Association for the Study of the Liver
  86. PCDHB14 promotes ferroptosis and is a novel tumor suppressor in hepatocellular carcinoma.2022Oncogene
  87. The potential of CircRNA1002 as a biomarker in hepatitis B virus-related hepatocellular carcinoma.2022PeerJ免费全文
  88. Analysis of mutations in DNA damage repair pathway gene in Chinese patients with hepatocellular carcinoma.2022Scientific reports免费全文
  89. Identification and validation of a novel pyroptosis-related lncRNAs signature associated with prognosis and immune regulation of hepatocellular carcinoma.2022Scientific reports免费全文
  90. A new model based inflammatory index and tumor burden score (TBS) to predict the recurrence of hepatocellular carcinoma (HCC) after liver resection.2022Scientific reports免费全文
  91. Automated machine learning for differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma on multiphasic MRI.2022Scientific reports免费全文
  92. Role of CD68 in tumor immunity and prognosis prediction in pan-cancer.2022Scientific reports免费全文
  93. Proteomic analysis of small extracellular vesicles from the plasma of patients with hepatocellular carcinoma.2022World journal of surgical oncology免费全文
  94. YTH domain family: potential prognostic targets and immune-associated biomarkers in hepatocellular carcinoma.2021Aging免费全文
  95. Integrated analysis of expression, prognostic value and immune infiltration of GSDMs in hepatocellular carcinoma.2021Aging免费全文
  96. Six genes involved in prognosis of hepatocellular carcinoma identified by Cox hazard regression.2021BMC bioinformatics免费全文
  97. Serum epidermal growth factor-like domain 7 serves as a novel diagnostic marker for early hepatocellular carcinoma.2021BMC cancer免费全文
  98. Loss of androgen receptor promotes HCC invasion and metastasis via activating circ-LNPEP/miR-532-3p/RAB9A signal under hypoxia.2021Biochemical and biophysical research communications
  99. Long Noncoding RNA TRIM52-AS1 Sponges miR-514a-5p to Facilitate Hepatocellular Carcinoma Progression Through Increasing MRPS18A.2021Cancer biotherapy & radiopharmaceuticals
  100. STMN2 mediates nuclear translocation of Smad2/3 and enhances TGFβ signaling by destabilizing microtubules to promote epithelial-mesenchymal transition in hepatocellular carcinoma.2021Cancer letters
  101. NAD(P)HX epimerase downregulation promotes tumor progression through ROS/HIF-1α signaling in hepatocellular carcinoma.2021Cancer science免费全文
  102. GNA14's interaction with RACK1 inhibits hepatocellular carcinoma progression through reducing MAPK/JNK and PI3K/AKT signaling pathway.2021Carcinogenesis免费全文
  103. Programmed cell death 10 promotes metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma via PP2Ac-mediated YAP activation.2021Cell death & disease免费全文
  104. BTB/POZ domain-containing protein 7/hypoxia-inducible factor 1 alpha signalling axis modulates hepatocellular carcinoma metastasis.2021Clinical and translational medicine免费全文
  105. EB2 promotes hepatocellular carcinoma proliferation and metastasis via MAPK/ERK pathway by modulating microtubule dynamics.2021Clinical science (London, England : 1979)
  106. Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients2021Clinics and research in hepatology and gastroenterology
  107. Construction of a Ferroptosis-Related Nine-lncRNA Signature for Predicting Prognosis and Immune Response in Hepatocellular Carcinoma.2021Frontiers in immunology免费全文
  108. Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody.2021Frontiers in immunology免费全文
  109. Integrative Transcriptomic, Proteomic and Functional Analysis Reveals ATP1B3 as a Diagnostic and Potential Therapeutic Target in Hepatocellular Carcinoma.2021Frontiers in immunology免费全文
  110. A new survival model based on ion channel genes for prognostic prediction in hepatocellular carcinoma.2021Genomics
  111. The functional roles, cross-talk and clinical implications of m6A modification and circRNA in hepatocellular carcinoma.2021International journal of biological sciences免费全文
  112. The strategy and efficacy of prophylaxis against hepatitis B virus recurrence after liver transplantation for HBV-related diseases in the era of potent nucleos(t)ide analogues: A meta-analysis.2021Journal of digestive diseases
  113. Atractylenolide III predisposes miR-195-5p/FGFR1 signaling axis to exert tumor-suppressive functions in liver cancer.2021Journal of food biochemistry
  114. Prognostic Nutritional Index and Systemic Immune-Inflammation Index Predict the Prognosis of Patients with HCC.2021Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract免费全文
  115. Hepatic macrophages: Key players in the development and progression of liver fibrosis.2021Liver international : official journal of the International Association for the Study of the Liver
  116. Microvascular invasion, an important clinical feature that should be deeply explored in hepatocellular carcinoma.2021Liver international : official journal of the International Association for the Study of the Liver
  117. ATE1 Inhibits Liver Cancer Progression through RGS5-Mediated Suppression of Wnt/β-Catenin Signaling.2021Molecular cancer research : MCR免费全文
  118. Deregulated 14-3-3ζ and methionine adenosyltransferase α1 interplay promotes liver cancer tumorigenesis in mice and humans.2021Oncogene免费全文
  119. Integrated Transcriptomic Analysis Revealed Hub Genes and Pathways Involved in Sorafenib Resistance in Hepatocellular Carcinoma.2021Pathology oncology research : POR免费全文
中文论文(未计入)1
  1. [Research progress of serum biomarkers for early screening of hepatocellular carcinoma].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)15
  1. JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study邀请入组NCT06882876牵头方I期2025-07 启动
  2. Study on the Treatment of Hepatitis B Virus(HBV) Infected Individuals With Peginterferon α-2b Combined With NA.正在招募NCT06746701牵头方2023-05 启动
  3. Antiviral Therapy for Patients With Liver Cancer After Surgery正在招募NCT05466565牵头方2021-12 启动
  4. An Organoid-on-chips Technique Based on Biopsy Samples and Its Efficacy in Predicting the Response to HAI in HCC已完成NCT05932836牵头方2023-03 启动
  5. Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma状态不明NCT05240404牵头方II期2020-07 启动
  6. Thermal Ablation Followed by Immunotherapy for HCC状态不明NCT03864211牵头方I/II期2019-06 启动
  7. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.正在招募NCT05862337研究中心III期2023-05 启动
  8. A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification状态不明NCT05313282研究中心III期2022-06 启动
  9. A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET)状态不明NCT05214339研究中心II期2022-03 启动
  10. A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev进行中,不再招募NCT04649489研究中心III期2021-04 启动
  11. Detection Evaluation of a Novel Blood-based DNA Methylation Assay in Early-stage Hepatocellular Carcinoma Patients状态不明NCT05343832研究中心2021-11 启动
  12. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)进行中,不再招募NCT04344158研究中心III期2020-08 启动
  13. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC已完成NCT04723004研究中心III期2020-10 启动
  14. Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients状态不明NCT02956772研究中心II期2016-11 启动
  15. A Study to Evaluate SHR-1210 in Subjects With Advanced HCC已完成NCT02989922研究中心II期2016-11 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 35 篇,占 0.4%。

牵头论文
35
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 7720212022: 9920222023: 121220232024: 4420242025: 332025

长沙有 4 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
    分期
    未注明
    开始
    2023-09
    登记号
    NCT06035250

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、南宁、天津、广州、昆明、沈阳、福州、苏州、郑州、长沙、青岛

  2. 正在招募
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    分期
    I/II期
    开始
    2022-01
    登记号
    NCT05150691

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 34 家列出的医院为研究中心上海、北京、南宁、厦门、合肥、天津、安阳、广州、徐州、无锡、杭州、武汉、沈阳、济南、温州、烟台、石家庄、蚌埠、西安、郑州、重庆、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题早期发现与内镜腹膜转移与晚期影像与人工智能
论文中的科室肿瘤内科消化/肝病科普外/肝胆胰外科病理/检验科
牵头的论文35
  1. Enhancing gastric ultrasound training with standardized patient-based drinking simulation: a self-controlled study.2025BMC medical education免费全文
  2. High-fidelity optical platform for multiplex glutathione profiling links redox dynamics to tumor progression and auxiliary diagnosis.2025Biosensors & bioelectronics
  3. Characterization of Bozitinib as a potential therapeutic agent for MET-amplified gastric cancer.2025Communications biology免费全文
  4. PMEPA1 promotes gastric cancer cell proliferation by regulating the ubiquitin-mediated degradation of 14-3-3σ and promoting cell cycle progression.2024Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas免费全文
  5. Exosomal miR-502-5p suppresses the progression of gastric cancer by repressing angiogenesis through the Wnt/β-catenin pathway.2024Irish journal of medical science
  6. Facilitating endoscopic full-thickness resection for gastric submucosal tumors with a novel snare traction method (with video).2024Journal of gastroenterology and hepatology
  7. A nomogram combining neutrophil to lymphocyte ratio (NLR) and prognostic nutritional index (PNI) to predict distant metastasis in gastric cancer.2024Scientific reports免费全文
  8. Single-cell profiling reveals tumour cell heterogeneity accompanying a pre-malignant and immunosuppressive microenvironment in gastric adenocarcinoma.2023Clinical and translational medicine免费全文
  9. Classification of precancerous lesions based on fusion of multiple hierarchical features.2023Computer methods and programs in biomedicine
  10. Gastric Cancer with Sarcopenia: an Area Worth Focusing On.2023Current treatment options in oncology
  11. Simultaneous incision and suturing of a large wound in the full-layer resection of stromal tumor under the traction of a snare -- a new method of endoscopic suturing.2023Endoscopy免费全文
  12. Traction and resection in treating gastric submucosal tumor growing extraluminally by using two snares like a ropeway.2023Endoscopy免费全文
  13. Early gastric mucosa-associated lymphoid tissue lymphoma treated by endoscopic submucosal dissection.2023Endoscopy免费全文
  14. Systematic evaluation of the safety and therapeutic effects of para-aortic lymphadenectomy for advanced gastric cancer: a systematic review and meta-analysis.2023European review for medical and pharmacological sciences
  15. FLOT1 promotes gastric cancer progression and metastasis through BCAR1/ERK signaling.2023International journal of biological sciences免费全文
  16. Analysis of genomic and immune intratumor heterogeneity in linitis plastica via multiregional exome and T-cell receptor sequencing.2023Molecular oncology免费全文
  17. Incidence trends and survival analysis of appendiceal tumors in the United States: Primarily changes in appendiceal neuroendocrine tumors.2023PloS one免费全文
  18. Comprehensive analysis regarding the prognostic significance of downregulated ferroptosis-related gene AKR1C2 in gastric cancer and its underlying roles in immune response.2023PloS one免费全文
  19. Comparison of endoscopic full-thickness resection and ligation-assisted endoscopic full-thickness resection for small (≤ 1.5 cm) gastric subepithelial tumors originating from muscularis propria.2023Surgical endoscopy
  20. The downregulated drug-metabolism related ALDH6A1 serves as predictor for prognosis and therapeutic immune response in gastric cancer.2022Aging免费全文
  21. miR-511-5p Suppresses Cell Migration, Invasion and Epithelial-Mesenchymal Transition Through Targeting PAK2 in Gastric Cancer.2022Biochemical genetics
  22. Genomic clonal evolution correlated with phenotype and prognosis in gastric cancer.2022Clinical and translational medicine免费全文
  23. E2F5 promotes proliferation and invasion of gastric cancer through directly upregulating UBE2T transcription.2022Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  24. Extracellular Vesicles Promote the Formation of Pre-Metastasis Niche in Gastric Cancer.2022Frontiers in immunology免费全文
  25. Study on the Expression of β-1,3-N-acetylglucosaminyltransferase 3 in Gastric Cancer and the Mechanism Promoting Gastric Cancer Progression Based on the Extraction Method of Nanomagnetic Beads.2022Journal of biomedical nanotechnology
  26. Establishment and Validation for Predicting the Lymph Node Metastasis in Early Gastric Adenocarcinoma.2022Journal of healthcare engineering免费全文
  27. Identification of a Hypoxia-Angiogenesis lncRNA Signature Participating in Immunosuppression in Gastric Cancer.2022Journal of immunology research免费全文
  28. CAF-derived midkine promotes EMT and cisplatin resistance by upregulating lncRNA ST7-AS1 in gastric cancer.2022Molecular and cellular biochemistry
  29. Pretreatment neutrophil-to-lymphocyte ratio predicts the benefit of gastric cancer patients with systemic therapy.2021Aging免费全文
  30. EBV as a high infection risk factor promotes RASSF10 methylation and induces cell proliferation in EBV-associated gastric cancer.2021Biochemical and biophysical research communications
  31. Endoscopic management of the rare situation where a gastric stromal tumor specimen falls into the nasopharynx.2021Endoscopy
  32. Protective role of astragaloside IV in gastric cancer through regulation of microRNA-195-5p-mediated PD-L1.2021Immunopharmacology and immunotoxicology
  33. Progress of Gastric Cancer Surgery in the era of Precision Medicine.2021International journal of biological sciences免费全文
  34. Genome Instability-Related miRNAs Predict Survival, Immune Landscape, and Immunotherapy Responses in Gastric Cancer.2021Journal of immunology research免费全文
  35. EphA2-YES1-ANXA2 pathway promotes gastric cancer progression and metastasis.2021Oncogene免费全文
中文论文(未计入)2
  1. Predictive value of preoperative L3-SMI, AGR, and PNI for overall survival in patients undergoing radical gastrectomy for gastric cancer.2025Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences免费全文
  2. Gender differences in systemic inflammatory and nutritional index following radical surgery for advanced gastric cancer.2024Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)19
  1. The Advantages and Disadvantages of Linear Anastomat and Tubular Anastomat in Radical Gastrectomy of Distal Gastric Cancer进行中,不再招募NCT07080879牵头方不分期2023-06 启动
  2. Clinical Study of Propranolol Combined With Neoadjuvant Chemotherapy in Gastric Cancer状态不明NCT04005365牵头方(推断)II期2019-11 启动
  3. AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy正在招募NCT06035250研究中心2023-09 启动
  4. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors正在招募NCT05150691研究中心I/II期2022-01 启动
  5. Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)进行中,不再招募NCT06710132研究中心I/II期2025-01 启动
  6. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression已完成NCT05052801研究中心III期2022-03 启动
  7. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.已终止NCT05111626研究中心III期2022-03 启动
  8. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer进行中,不再招募NCT05180734研究中心III期2022-02 启动
  9. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression状态不明NCT04714190研究中心III期2021-03 启动
  10. Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors已完成NCT04400383研究中心I期2020-06 启动
  11. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)进行中,不再招募NCT04152499研究中心I/II期2020-02 启动
  12. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer状态不明NCT04486651研究中心III期2020-09 启动
  13. Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer进行中,不再招募NCT04208347研究中心II/III期2019-12 启动
  14. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)已完成NCT03675737研究中心III期2018-11 启动
  15. A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer已完成NCT03694522研究中心II期2018-09 启动
  16. Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)已完成NCT03615326研究中心III期2018-10 启动
  17. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension已撤回NCT04859582研究中心III期2018-11 启动
  18. Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)已终止NCT03019588研究中心III期2017-02 启动
  19. Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)状态不明NCT02461407研究中心II/III期2015-06 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

肝母细胞瘤

Hepatoblastoma

2021–2025 年中国大陆作者发表的 154 篇肝母细胞瘤 PubMed 英文论文中,这家医院牵头了 5 篇,占 3.2%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 1120222023: 0020232024: 1120242025: 112025

长沙有 3 家医院列在肝母细胞瘤下全国有 88 家医院列在肝母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科

这些论文过半是实验室或动物研究。

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

长沙有 6 家医院列在视网膜母细胞瘤下全国有 196 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

脊索瘤

Chordoma

2021–2025 年中国大陆作者发表的 105 篇脊索瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.9%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

长沙有 6 家医院列在脊索瘤下全国有 88 家医院列在脊索瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。

这些数字背后的记录
论文中的科室耳鼻喉/头颈外科
牵头的论文1
  1. The prognostic significance of different degrees of resection of skull base chordoma.2022Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
早期论文(2016–2020 年)2
  1. Prognostic Factors in Patients With Spinal Chordoma: An Integrative Analysis of 682 Patients.2017Neurosurgery
  2. [Pretemporal transcavernous approach tailored surgery of cavernous sinus tumors: a consecutive series of 31 cases report].2016Zhonghua wai ke za zhi [Chinese journal of surgery]

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 15 篇,占 0.7%。

牵头论文
15
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 2220222023: 2220232024: 3320242025: 552025

长沙有 14 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室神经外科
牵头的论文15
  1. PLEKHF1 Induces Mitochondrial Dysfunction to Inhibit Osteosarcoma Growth and Metastasis.2025IUBMB life
  2. Demethylase, ALKBH1, regulates osteosarcoma chemosensitivity through FZD8/Wnt/β-catenin signaling pathway in the m7G manner.2025International journal of biological macromolecules
  3. Eriodictyol-cisplatin coated nanomedicine synergistically promote osteosarcoma cells ferroptosis and chemosensitivity.2025Journal of nanobiotechnology
  4. CYFIP1 coordinate with RNMT to induce osteosarcoma cuproptosis via AURKAIP1 m7G modification.2025Molecular medicine (Cambridge, Mass.)
  5. Identification and validation of SAC3D1 as a prognostic biomarker promoting the development of osteosarcoma.2025Scientific reports
  6. Exploring the relationship between metabolism and immune microenvironment in osteosarcoma based on metabolic pathways.2024Journal of biomedical science
  7. Osteosarcoma neutrophil extracellular trap network-associated gene recurrence and metastasis model.2024Journal of cancer research and clinical oncology
  8. The immune cell infiltration-associated molecular subtypes and gene signature predict prognosis for osteosarcoma patients.2024Scientific reports
  9. Comprehensive analysis of copper-metabolism-related genes about prognosis and immune microenvironment in osteosarcoma.2023Scientific reports
  10. Use of LARS for soft tissue function reconstruction during tumor-type hemi-shoulder replacement achieves a good prognosis: a retrospective cohort study.2023World journal of surgical oncology
  11. METTL3 upregulates COPS5 expression in osteosarcoma in an m6A-related manner to promote osteosarcoma progression.2022Experimental cell research
  12. Construction and validation model of necroptosis-related gene signature associates with immunity for osteosarcoma patients.2022Scientific reports
  13. Ferroptosis-related gene signature associates with immunity and predicts prognosis accurately in patients with osteosarcoma.2021Cancer science
  14. circPVT1 promotes osteosarcoma glycolysis and metastasis by sponging miR-423-5p to activate Wnt5a/Ror2 signaling.2021Cancer science
  15. A Novel Treatment for Ewing's Sarcoma: Chimeric Antigen Receptor-T Cell Therapy.2021Frontiers in immunology
中文论文(未计入)1
  1. Clinical application of LARS tumor tube in joint function reconstruction of tumor type artificial hip replacement.2024Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
早期论文(2016–2020 年)17
  1. Functionalized BaTiO3 enhances piezoelectric effect towards cell response of bone scaffold.2020Colloids and surfaces. B, Biointerfaces
  2. miR‑181b‑p53 negative feedback axis regulates osteosarcoma cell proliferation and invasion.2020International journal of molecular medicine
  3. Letter to the Editor on the article "Long non-coding RNA MALAT1 as a valuable biomarker for prognosis in osteosarcoma: A systematic review and meta-analysis" (Int J Surg 2019; Nov 15;72:206-213. doi: 10.1016/j.ijsu.2019.11.004. [Epub ahead 2020International journal of surgery (London, England)
  4. miR-139-mediated NOTCH1 regulation is crucial for the inhibition of osteosarcoma progression caused by resveratrol.2020Life sciences
  5. Rab22a-NeoF1: a promising target for osteosarcoma patients with lung metastasis.2020Signal transduction and targeted therapy
  6. Fructose-coated Angstrom silver inhibits osteosarcoma growth and metastasis via promoting ROS-dependent apoptosis through the alteration of glucose metabolism by inhibiting PDK.2020Theranostics
  7. The possible role of insulin-like growth factor-1 in osteosarcoma.2019Current problems in cancer
  8. MicroRNA-340-5p suppresses osteosarcoma development by down-regulating the Wnt/β-catenin signaling pathway via targeting the STAT3 gene.2019European review for medical and pharmacological sciences
  9. Angiogenesis Process in Osteosarcoma: An Updated Perspective of Pathophysiology and Therapeutics.2019The American journal of the medical sciences
  10. CXCR4-mediated osteosarcoma growth and pulmonary metastasis is suppressed by MicroRNA-613.2018Cancer science
  11. Distraction-suppression effect on osteosarcoma.2018Medical hypotheses
  12. Is double-approach surgery and tenodesis without a gastrocnemius flap better for dealing with proximal fibular osteosarcoma?2018World journal of surgical oncology
  13. Nd-induced honeycomb structure of intermetallic phase enhances the corrosion resistance of Mg alloys for bone implants.2017Journal of materials science. Materials in medicine
  14. MicroRNA-34a inhibits tumor invasion and metastasis in osteosarcoma partly by effecting C-IAP2 and Bcl-2.2017Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  15. Visfatin triggers the in vitro migration of osteosarcoma cells via activation of NF-κB/IL-6 signals.2016European journal of pharmacology
  16. JNK pathway in osteosarcoma: pathogenesis and therapeutics.2016Journal of receptor and signal transduction research
  17. MALAT1 promotes osteosarcoma development by targeting TGFA via MIR376A.2016Oncotarget

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.8%。

牵头论文
4
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 1120232024: 1120242025: 112025

长沙有 3 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST
    分期
    不分期
    开始
    2023-02
    登记号
    NCT05751733

    年龄 18 岁 至 未注明(登记的条件)

    牵头:中南大学湘雅医院长沙

  2. 正在招募
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    分期
    II/III期
    开始
    2026-05
    登记号
    NCT07379047

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、成都、昆明、杭州、武汉、济南、石家庄、福州、贵阳、郑州、重庆、长春、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肿瘤内科消化/肝病科影像/核医学科
牵头的论文4
  1. The feasibility of endoscopic resection for esophageal gastrointestinal stromal tumor.2025Surgical endoscopy
  2. KIT mutations and expression: current knowledge and new insights for overcoming IM resistance in GIST.2024Cell communication and signaling : CCS
  3. CT-based assessment of sarcopenia for differentiating wild-type from mutant-type gastrointestinal stromal tumor.2023Scientific reports
  4. Endoscopic management of the rare situation where a gastric stromal tumor specimen falls into the nasopharynx.2021Endoscopy
早期论文(2016–2020 年)6
  1. Preoperative adjuvant therapy for locally advanced and recurrent/metastatic gastrointestinal stromal tumors: a retrospective study.2020World journal of surgical oncology
  2. Metastatic pattern and prognosis of gastrointestinal stromal tumor (GIST): a SEER-based analysis.2019Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  3. [Correlation of CT imaging features and CT texture analysis parameters with pathologic risk stratification 
in gastric stromal tumors].2019Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  4. [Option for different surgeries in treating small gastrointestinal stromal tumors].2018Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  5. Four synchronous primary cancers of the aerodigestive tract and thyroid.2017Asian cardiovascular & thoracic annals
  6. Concomitant stromal tumor and early cancer of the stomach: What should be done?2017Medicine
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST正在招募NCT05751733牵头方不分期2023-02 启动
  2. Entacapone Combination With Imatinib for Treatment of GIST已完成NCT04006769牵头方早期I期2020-10 启动
  3. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)正在招募NCT07379047研究中心II/III期2026-05 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.4%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 1120232024: 1120242025: 002025

长沙有 8 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室神经外科神经内科
牵头的论文4
  1. HNRNPA2B1 and HNRNPR stabilize ASCL1 in an m6A-dependent manner to promote neuroblastoma progression.2024Biochimica et biophysica acta. Molecular basis of disease
  2. Exosomal circBBS2 inhibits ferroptosis by targeting miR-494 to activate SLC7A11 signaling in ischemic stroke.2023FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  3. Value of Immunohistochemical Expression of Apelin, Succinate Dehydrogenase B, Chromogranin B, Human Epidermal Growth Factor Receptor-2, Contactin 4, and Succinyl-CoA Synthetase Subunit Beta in Differentiating Metastatic From Non-Metastatic 2022Frontiers in endocrinology
  4. Transplantation of Nasal Olfactory Mucosa Mesenchymal Stem Cells Benefits Alzheimer's Disease.2022Molecular neurobiology
早期论文(2016–2020 年)5
  1. PHF20 collaborates with PARP1 to promote stemness and aggressiveness of neuroblastoma cells through activation of SOX2 and OCT4.2018Journal of molecular cell biology
  2. Exogenous Hydrogen Sulfide Protects SH-SY5Y Cells from OGD/RInduced Injury.2017Current molecular medicine
  3. Novel multiple tyrosine kinase inhibitor ponatinib inhibits bFGF-activated signaling in neuroblastoma cells and suppresses neuroblastoma growth in vivo.2017Oncotarget
  4. [Effect of neuroglobin on oxygen-glucose deprivation and reoxygenation induced autophagy in a human neuroblastoma cell line].2017Zhonghua yi xue za zhi
  5. Genome-wide analysis of DNA methylation during antagonism of DMOG to MnCl2-induced cytotoxicity in the mouse substantia nigra.2016Scientific reports

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

长沙有 3 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 8 篇,占 0.5%。

牵头论文
8
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 3320222023: 0020232024: 2220242025: 112025

长沙有 4 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的多发性骨髓瘤开放试验。

这些数字背后的记录
研究主题联合用药干细胞移植肾脏与骨骼并发症
论文中的科室病理/检验科

这些论文过半是实验室或动物研究。

牵头的论文8
  1. Construction of a machine learning-based screening model for IgD myeloma.2025Clinica chimica acta; international journal of clinical chemistry
  2. Sulforaphane inhibits multiple myeloma cell-induced osteoclast differentiation and macrophage proliferation by elevating ferroportin1.2024Cancer chemotherapy and pharmacology
  3. Predictive factors for peripheral blood stem cell mobilization in multiple myeloma in the era of novel therapies: A single-center experience.2024Cancer medicine免费全文
  4. Genetic Aberrations and Interaction of NEK2 and TP53 Accelerate Aggressiveness of Multiple Myeloma.2022Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  5. Deubiquitylase USP12 induces pro-survival autophagy and bortezomib resistance in multiple myeloma by stabilizing HMGB1.2022Oncogene
  6. CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation.2022The Journal of clinical investigation免费全文
  7. An interactive nomogram based on clinical and molecular signatures to predict prognosis in multiple myeloma patients.2021Aging免费全文
  8. TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies.2021The Journal of clinical investigation免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
  1. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)已完成NCT04939142研究中心III期2021-07 启动
  2. Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)状态不明NCT03975907研究中心I/II期2019-06 启动
  3. Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)已终止NCT01947309研究中心2013-11 启动
  4. Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year已完成NCT02348528研究中心II期2012-09 启动
  5. Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma已完成NCT01593410研究中心II期2010-08 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

B 细胞急性淋巴细胞白血病

B-cell acute lymphoblastic leukaemia

2021–2025 年中国大陆作者发表的 225 篇B 细胞急性淋巴细胞白血病 PubMed 英文论文中,这家医院牵头了 4 篇,占 1.8%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 2220242025: 222025

长沙有 4 家医院列在B 细胞急性淋巴细胞白血病下全国有 90 家医院列在B 细胞急性淋巴细胞白血病下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
    分期
    II/III期
    开始
    2025-01
    登记号
    NCT06764238

    年龄 1 个月 至 18 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所);另有 24 家列出的医院为研究中心上海、南京、南宁、南昌、合肥、天津、广州、成都、武汉、济南、深圳、福州、苏州、西安、贵阳、重庆、长沙、青岛

  2. 正在招募
    Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
    分期
    II/III期
    开始
    2025-03
    登记号
    NCT06882057

    年龄 1 岁 至 18 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所);另有 23 家列出的医院为研究中心上海、南京、南宁、南昌、合肥、天津、广州、成都、武汉、济南、福州、苏州、西安、贵阳、重庆、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题儿童费城染色体与遗传学抗体与靶向药物
论文中的科室儿科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

再生障碍性贫血

Aplastic anaemia

2021–2025 年中国大陆作者发表的 412 篇再生障碍性贫血 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.7%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 1120232024: 0020242025: 002025

长沙有 2 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的再生障碍性贫血开放试验。

这些数字背后的记录
研究主题干细胞移植儿童

打开 PubMed 检索ClinicalTrials.gov

血液疾病

噬血细胞性淋巴组织细胞增生症

Haemophagocytic lymphohistiocytosis

2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

长沙有 4 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的噬血细胞性淋巴组织细胞增生症开放试验。

这些数字背后的记录
研究主题治疗方案

打开 PubMed 检索ClinicalTrials.gov

血液疾病

β 地中海贫血

Beta thalassaemia

2021–2025 年中国大陆作者发表的 312 篇β 地中海贫血 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

长沙有 5 家医院列在β 地中海贫血下全国有 157 家医院列在β 地中海贫血下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的β 地中海贫血开放试验。

这些数字背后的记录
牵头的论文1
  1. CRISPR-Cas9-mediated gene editing of the BCL11A enhancer for pediatric β0/β0 transfusion-dependent β-thalassemia.2022Nature medicine
中文论文(未计入)1
  1. [Rare thalassemia caused by novel nucleotide variants in the globin gene: four case reports and literature review].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia进行中,不再招募NCT05577312研究中心I/II期2022-11 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血友病 A

Haemophilia A

2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

长沙有 6 家医院列在血友病 A下全国有 160 家医院列在血友病 A下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
    分期
    III期
    开始
    2025-03
    登记号
    NCT06833983

    年龄 18 岁 至 65 岁;仅男性(登记的条件)

    牵头方不是列出的医院;另有 13 家列出的医院为研究中心兰州、北京、南京、南昌、合肥、唐山、天津、广州、昆明、武汉、济南、郑州、长沙

  2. 正在招募
    Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
    分期
    II/III期
    开始
    2024-01
    登记号
    NCT06111638

    年龄 18 岁 至 未注明;仅男性(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心Xi’an、北京、天津、广州、成都、昆明、武汉、苏州、贵阳、长沙

  3. 正在招募
    An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency
    分期
    I/II期
    开始
    2024-05
    登记号
    NCT07644832

    年龄 18 岁 至 65 岁(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心兰州、合肥、太原、济南、西安、郑州、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
牵头的论文1
  1. Joint status and related risk factors in patients with severe hemophilia A: a single-center cross-sectional study.2022Hematology (Amsterdam, Netherlands)
早期论文(2016–2020 年)2
  1. A study of the stressors and coping behaviors of parents of Chinese hemophilic children.2017Journal of child health care : for professionals working with children in the hospital and community
  2. In situ genetic correction of F8 intron 22 inversion in hemophilia A patient-specific iPSCs.2016Scientific reports
它在 ClinicalTrials.gov 上的全部试验(任何状态)21
  1. To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A正在招募NCT06833983研究中心III期2025-03 启动
  2. Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs正在招募NCT06111638研究中心II/III期2024-01 启动
  3. An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency正在招募NCT07644832研究中心I/II期2024-05 启动
  4. A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A进行中,不再招募NCT06297655研究中心III期2024-11 启动
  5. Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with Inhibitor已完成NCT06289166研究中心II期2024-03 启动
  6. A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A已完成NCT05707351研究中心III期2023-03 启动
  7. A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A进行中,不再招募NCT05685238研究中心III期2023-02 启动
  8. Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein已完成NCT06142552研究中心III期2023-12 启动
  9. Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without Inhibitor已完成NCT05619926研究中心II期2023-01 启动
  10. A Phase I of SS109 in Hemophilia A or and B With Inhibitors已完成NCT05651061研究中心I期2022-12 启动
  11. Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitor状态不明NCT05487976研究中心III期2022-04 启动
  12. Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)已完成NCT05082116研究中心III期2021-09 启动
  13. Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A已完成NCT04845399研究中心III期2021-04 启动
  14. A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors已完成NCT05053139研究中心III期2021-12 启动
  15. An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.已完成NCT04456387研究中心III期2020-10 启动
  16. Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.状态不明NCT04061109研究中心III期2019-05 启动
  17. Pharmacokinetics Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.状态不明NCT04060836研究中心I期2019-05 启动
  18. Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants已完成NCT03315455研究中心III期2018-04 启动
  19. Pharmacokinetic Study of SCT800 in Previously Treated Patients With Hemophilia A状态不明NCT02888223研究中心I期2016-09 启动
  20. Efficacy and Safety Study of SCT800 for On-demand Treatment With in Patients With Hemophilia A状态不明NCT02921945研究中心III期2016-10 启动
  21. China ADVATE PTP Study已完成NCT02170402研究中心IV期2014-06 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

非典型溶血性尿毒症综合征

Atypical haemolytic uraemic syndrome

2021–2025 年没有牵头非典型溶血性尿毒症综合征的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

长沙有 2 家医院列在非典型溶血性尿毒症综合征下全国有 31 家医院列在非典型溶血性尿毒症综合征下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的非典型溶血性尿毒症综合征开放试验。

这些数字背后的记录
论文中的科室儿科
中文论文(未计入)1
  1. [Ultra-early administration of eculizumab in a child with atypical hemolytic uremic syndrome: a case report].2025Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血栓性血小板减少性紫癜

Thrombotic thrombocytopenic purpura

2021–2025 年中国大陆作者发表的 64 篇血栓性血小板减少性紫癜 PubMed 英文论文中,这家医院牵头了 2 篇,占 3.1%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

长沙有 5 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血栓性血小板减少性紫癜开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

范可尼贫血

Fanconi anaemia

2021–2025 年中国大陆作者发表的 68 篇范可尼贫血 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

长沙有 2 家医院列在范可尼贫血下全国有 40 家医院列在范可尼贫血下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的范可尼贫血开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

视神经脊髓炎谱系疾病

Neuromyelitis optica spectrum disorder

2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 5 篇,占 1.0%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 1120232024: 0020242025: 112025

长沙有 2 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    分期
    II/III期
    开始
    2024-07
    登记号
    NCT06413654

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 27 家列出的医院为研究中心北京、厦门、合肥、哈尔滨、天津、太原、广州、成都、昆明、杭州、武汉、沈阳、济南、温州、石家庄、福州、郑州、长沙

  2. 正在招募
    A Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD)
    分期
    II期
    开始
    2023-05
    登记号
    NCT06697535

    年龄 18 岁 至 65 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题急性发作治疗抗体与诊断预防复发
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgG4相关性疾病

IgG4-related disease

2021–2025 年中国大陆作者发表的 246 篇IgG4相关性疾病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

长沙有 2 家医院列在IgG4相关性疾病下全国有 46 家医院列在IgG4相关性疾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的IgG4相关性疾病开放试验。

这些数字背后的记录
研究主题头颈、眼眶与唾液腺
论文中的科室耳鼻喉/头颈外科普外/肝胆胰外科消化/肝病科
牵头的论文1
  1. Gastrointestinal: A case of IgG4-related disease involving intestinal tract and orbital cavity.2023Journal of gastroenterology and hepatology
中文论文(未计入)1
  1. [Analysis of diagnosis and treatment of IgG4-related disease involving the nasal cavity and skull base(with 8 case reports)].2025Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery免费全文

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 20 篇,占 4.0%。

牵头论文
20
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
6
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 4420222023: 3320232024: 7720242025: 332025

长沙有 4 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下

这家医院参与的开放试验 6

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis
    分期
    II期
    开始
    2026-08
    登记号
    NCT07622342

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心上海、长沙

  2. 正在招募
    Myasthenia Gravis Registry in China
    分期
    未注明
    开始
    2024-02
    登记号
    NCT06241521

    年龄未注明(登记的条件)

    牵头:复旦大学附属华山医院;另有 15 家列出的医院为研究中心上海、北京、南昌、天津、广州、徐州、成都、苏州、西安、郑州、重庆、长春、长沙

  3. 正在招募
    A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
    分期
    II/III期
    开始
    2024-07
    登记号
    NCT06447597

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、南昌、广州、成都、杭州、武汉、济南、西安、长春、长沙

  4. 正在招募
    Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
    分期
    III期
    开始
    2024-06
    登记号
    NCT06463587

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、北京、广州、成都、武汉、沈阳、石家庄、蚌埠、遵义、郑州、长春、长沙

  5. 正在招募
    Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
    分期
    II期
    开始
    2022-07
    登记号
    NCT05067348

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:空军军医大学唐都医院;另有 5 家列出的医院为研究中心上海、北京、天津、成都、西安、长沙

  6. 正在招募
    A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
    分期
    III期
    开始
    2021-07
    登记号
    NCT04951622

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、北京、天津、广州、成都、杭州、济南、福州、西安、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题抗体与诊断常规免疫治疗胸腺与胸腺切除
论文中的科室神经内科儿科肿瘤内科
牵头的论文20
  1. Association between antibody status and exacerbation in patients with myasthenia gravis who achieved minimal manifestation or better status.2025Journal of neurology
  2. Comparison of Efficacy Between Lymphoplasmapheresis and Plasma Exchange in Myasthenic Crisis.2025Muscle & nerve
  3. Circulating inflammatory proteins as pathogenic mediators and potential therapeutic targets in myasthenia gravis.2025Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  4. Treatment of juvenile myasthenia gravis with tacrolimus: A cohort study.2024European journal of neurology免费全文
  5. Mendelian randomization and colocalization analysis reveal novel drug targets for myasthenia gravis.2024Human genomics免费全文
  6. Immune repertoire profiling in myasthenia gravis.2024Immunology and cell biology
  7. Diagnostic value of antibody concentration ratio for treatment-refractory myasthenia gravis.2024Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  8. Myasthenia gravis and five autoimmune diseases: a bidirectional Mendelian randomization study.2024Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  9. Comparative effectiveness and safety of intravenous methylprednisolone and tacrolimus monotherapy in ocular myasthenia gravis with unsatisfactory prednisone responses: a retrospective study.2024Orphanet journal of rare diseases免费全文
  10. Pediatric Ocular Myasthenia Gravis: Single-Center Experience.2024Pediatric neurology
  11. Latent tuberculosis infection in myasthenia gravis patients on immunosuppressive therapy: high incidence yet moderate reactivation rate.2023Annals of medicine免费全文
  12. Evidence for genetic causal relationships between gut microbiome, metabolites, and myasthenia gravis: a bidirectional Mendelian randomization study.2023Frontiers in immunology免费全文
  13. The value of postoperative radiotherapy in thymoma patients with myasthenia gravis.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  14. Risk factors associated with adverse pregnancy outcomes and postpartum exacerbation in women with myasthenia gravis.2022American journal of reproductive immunology (New York, N.Y. : 1989)
  15. Lymphoplasma Exchange Improves Myasthenia Gravis Exacerbations: A Retrospective Study in a Chinese Center.2022Frontiers in immunology免费全文
  16. Poor responses and adverse outcomes of myasthenia gravis after thymectomy: Predicting factors and immunological implications.2022Journal of autoimmunity
  17. Characteristics of myasthenia gravis in elderly patients: a retrospective study.2022Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  18. To Be or Not To Be Vaccinated: That Is a Question in Myasthenia Gravis.2021Frontiers in immunology免费全文
  19. Evaluation of outcome measures for myasthenia gravis subgroups.2021Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  20. Tacrolimus as Single-Agent Immunotherapy and Minimal Manifestation Status in Nonthymoma Myasthenia Gravis.2021Journal of immunology research免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)12
  1. A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis正在招募NCT07622342研究中心II期2026-08 启动
  2. A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.正在招募NCT06447597研究中心II/III期2024-07 启动
  3. Myasthenia Gravis Registry in China正在招募NCT06241521研究中心2024-02 启动
  4. Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)正在招募NCT06463587研究中心III期2024-06 启动
  5. Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis正在招募NCT05067348研究中心II期2022-07 启动
  6. A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis正在招募NCT04951622研究中心III期2021-07 启动
  7. A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)进行中,不再招募NCT06456580研究中心III期2024-07 启动
  8. A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis进行中,不再招募NCT06558279研究中心III期2024-09 启动
  9. Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis状态不明NCT05716035研究中心II/III期2023-04 启动
  10. Study of Telitacicept in Generalized Myasthenia Gravis已完成NCT05737160研究中心III期2023-03 启动
  11. A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis进行中,不再招募NCT05070858研究中心III期2021-12 启动
  12. A Study of TACI(Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor)-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis已完成NCT04302103研究中心II期2020-07 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

烟雾病

Moyamoya disease

2021–2025 年中国大陆作者发表的 356 篇烟雾病 PubMed 英文论文中,这家医院牵头了 6 篇,占 1.7%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 3320232024: 0020242025: 112025

长沙有 1 家医院列在烟雾病下全国有 47 家医院列在烟雾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的烟雾病开放试验。

这些数字背后的记录
研究主题影像与脑血流中风与出血血管重建手术
论文中的科室神经外科神经内科影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.8%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

长沙有 3 家医院列在抗 NMDA 受体脑炎下全国有 126 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录
论文中的科室神经内科儿科
牵头的论文2
  1. Clinical and radiological features, treatment responses and prognosis in pediatric patients with co-existing anti-N-methyl-D-aspartate receptor and myelin oligodendrocyte glycoprotein antibody-associated encephalitis: A single center study.2024Multiple sclerosis and related disorders
  2. Clinical features of adult patients with positive NMDAR-IgG coexisting with MOG-IgG.2024Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
中文论文(未计入)1
  1. [Clinical analysis of 9 children with refractory N-methyl-D-aspartate receptor antibody encephalitis children treated with tocilizumab].2024Zhonghua er ke za zhi = Chinese journal of pediatrics
早期论文(2016–2020 年)5
  1. A survey on pediatric anti-N-methyl-D-aspartate-receptor encephalitis treatment strategies in China.2020Chinese medical journal
  2. [Cryptococcal Encephalitis Complicating Anti-N-methyl-D-aspartate Receptor Encephalitis in an Immunosuppressed Patient].2020Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  3. [Clinical features of anti-N-methyl-D-aspartate receptor encephalitis and the concomitant seizure].2019Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  4. [Clinical analysis of 71 cases of anti-N-methyl-D-aspartate receptor encephalitis in children].2019Zhonghua er ke za zhi = Chinese journal of pediatrics
  5. Anti-N-methyl-d-aspartate receptor encephalitis in children of Central South China: Clinical features, treatment, influencing factors, and outcomes.2017Journal of neuroimmunology

打开 PubMed 检索ClinicalTrials.gov

其他疾病

大动脉炎

Takayasu arteritis

2021–2025 年中国大陆作者发表的 187 篇大动脉炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

长沙有 3 家医院列在大动脉炎下全国有 108 家医院列在大动脉炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。

这些数字背后的记录
论文中的科室风湿免疫科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.4%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 3320242025: 112025

长沙有 7 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    分期
    III期
    开始
    2026-09
    登记号
    NCT07687459

    年龄 40 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 45 家列出的医院为研究中心Yuncheng、上海、乌鲁木齐、北京、南京、南宁、南昌、南阳、厦门、合肥、呼和浩特、天津、太原、宁波、宜昌、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、海口、温州、石家庄、福州、西安、郑州、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室儿科
牵头的论文4
  1. Clinical characteristics and all-cause mortality in female patients with idiopathic pulmonary fibrosis in Chinese population.2025Journal of global health
  2. Smoking and Idiopathic Pulmonary Fibrosis: A Meta-analysis.2024Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
  3. Psoriasis may increase the risk of idiopathic pulmonary fibrosis: a two-sample Mendelian randomization study.2024Respiratory research
  4. Succinate promotes pulmonary fibrosis through GPR91 and predicts death in idiopathic pulmonary fibrosis.2024Scientific reports
早期论文(2016–2020 年)4
  1. Molecular pathogenesis involved in human idiopathic pulmonary fibrosis based on an integrated microRNA‑mRNA interaction network.2018Molecular medicine reports
  2. [Manifestations of the connective tissue associated interstitial lung disease under high resolution computed tomography].2017Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  3. The effect of H19-miR-29b interaction on bleomycin-induced mouse model of idiopathic pulmonary fibrosis.2016Biochemical and biophysical research communications
  4. miR‑221 targets HMGA2 to inhibit bleomycin‑induced pulmonary fibrosis by regulating TGF‑β1/Smad3-induced EMT.2016International journal of molecular medicine
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)正在招募NCT07687459研究中心III期2026-09 启动
  2. Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)已完成NCT05938920研究中心II期2023-06 启动
  3. A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis已终止NCT04552899研究中心III期2021-03 启动
  4. Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis已完成NCT01619085研究中心III期2012-06 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 23 篇,占 2.9%。

牵头论文
23
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 6620212022: 5520222023: 4420232024: 2220242025: 552025

长沙有 4 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录
论文中的科室神经内科影像/核医学科
牵头的论文23
  1. Brain metabolic imaging with 18 F-PET-CT and machine-learning clustering analysis reveal divergent metabolic phenotypes in patients with amyotrophic lateral sclerosis.2026European journal of nuclear medicine and molecular imaging
  2. Exploring the Causal Association Between 91 Circulating Inflammatory Proteins and Neurodegenerative Diseases: A Bidirectional Two-Sample Mendelian Randomization and Bioinformatics Analysis.2025Brain and behavior
  3. Shape Alterations of Subcortical Nuclei Correlate With Amyotrophic Lateral Sclerosis Progression.2025Brain and behavior
  4. Association of Reduced Brain Metabolism With Motor Function and Survival in Amyotrophic Lateral Sclerosis Patients With Neurofilament Heavy (NEFH) Gene Mutation.2025European journal of neurology
  5. Retinal alterations induced by amyotrophic lateral sclerosis: An analysis using optical coherence tomography.2025Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  6. Medulla oblongata dominated synaptic density network degeneration in amyotrophic lateral sclerosis.2025NeuroImage. Clinical
  7. Mutation and clinical analysis of the CLCC1 gene in amyotrophic lateral sclerosis patients from Central South China.2024Annals of clinical and translational neurology
  8. Association of TRMT2B gene variants with juvenile amyotrophic lateral sclerosis.2024Frontiers of medicine
  9. Neutralizing peripheral circulating IL1β slows the progression of ALS in a lentivirus-infected OPTNE478G mouse model.2023Animal models and experimental medicine
  10. Biomarkers in cerebrospinal fluid for amyotrophic lateral sclerosis phenotypes.2023Annals of clinical and translational neurology
  11. Brain metabolic signatures in patients with genetic and nongenetic amyotrophic lateral sclerosis.2023CNS neuroscience & therapeutics
  12. ALS-plus related clinical and genetic study from China.2023Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  13. Urinary p75ECD levels in patients with amyotrophic lateral sclerosis: a meta-analysis.2022Amyotrophic lateral sclerosis & frontotemporal degeneration
  14. CYLD variants identified in Alzheimer's disease and frontotemporal dementia patients.2022Annals of clinical and translational neurology
  15. Detection of changes in synaptic density in amyotrophic lateral sclerosis patients using 18 F-SynVesT-1 positron emission tomography.2022European journal of neurology
  16. Mitochondrial genome variations are associated with amyotrophic lateral sclerosis in patients from mainland China.2022Journal of neurology
  17. Association of variants in the KIF1A gene with amyotrophic lateral sclerosis.2022Translational neurodegeneration
  18. Genetics of frontotemporal dementia in China.2021Amyotrophic lateral sclerosis & frontotemporal degeneration
  19. A Step-by-Step Refined Strategy for Highly Efficient Generation of Neural Progenitors and Motor Neurons from Human Pluripotent Stem Cells.2021Cells
  20. Downregulation of TOP2 modulates neurodegeneration caused by GGGGCC expanded repeats.2021Human molecular genetics
  21. Spreading of pathological TDP-43 along corticospinal tract axons induces ALS-like phenotypes in Atg5+/- mice.2021International journal of biological sciences
  22. Mutation spectrum of amyotrophic lateral sclerosis in Central South China.2021Neurobiology of aging
  23. Rare, pathogenic variants in LRP10 are associated with amyotrophic lateral sclerosis in patients from mainland China.2021Neurobiology of aging
中文论文(未计入)1
  1. [Heterogeneity in the regulation of cellular stress responses by FUS gene mutations associated with amyotrophic lateral sclerosis].2025Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
早期论文(2016–2020 年)16
  1. Riluzole Exhibits No Therapeutic Efficacy on a Transgenic Rat model of Amyotrophic Lateral Sclerosis.2020Current neurovascular research
  2. Mutation analysis of GLT8D1 and ARPP21 genes in amyotrophic lateral sclerosis patients from mainland China.2020Neurobiology of aging
  3. Eye tracking metrics to screen and assess cognitive impairment in patients with neurological disorders.2020Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  4. The alteration of gut microbiome and metabolism in amyotrophic lateral sclerosis patients.2020Scientific reports
  5. Advances in genetics research in the pathogenesis of amyotrophic lateral sclerosis.2020Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  6. [Proteomic analysis of the cerebrospinal fluid from patients with amyotrophic lateral sclerosis based on tandem mass spectrometry technique].2019Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  7. Temporal Expression of Mutant TDP-43 Correlates with Early Amyotrophic Lateral Sclerosis Phenotype and Motor Weakness.2018Current neurovascular research
  8. ALS-Associated E478G Mutation in Human OPTN (Optineurin) Promotes Inflammation and Induces Neuronal Cell Death.2018Frontiers in immunology
  9. Identification of CHCHD2 mutations in patients with Alzheimer's disease, amyotrophic lateral sclerosis and frontotemporal dementia in China.2018Molecular medicine reports
  10. Mutation analysis of the TIA1 gene in Chinese patients with amyotrophic lateral sclerosis and frontotemporal dementia.2018Neurobiology of aging
  11. [Mutations of G38R and D40G cause amyotrophic lateral sclerosis by reducing Annexin A11 protein stability].2018Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  12. Mutations of CCNF gene is rare in patients with amyotrophic lateral sclerosis and frontotemporal dementia from Mainland China.2017Amyotrophic lateral sclerosis & frontotemporal degeneration
  13. Identification of CHCHD10 Mutation in Chinese Patients with Alzheimer Disease.2017Molecular neurobiology
  14. High prevalence of CHCHD10 mutation in patients with frontotemporal dementia from China.2016Brain : a journal of neurology
  15. Genetic and clinical analysis of spinocerebellar ataxia type 36 in Mainland China.2016Clinical genetics
  16. Screening of SOD1, FUS and TARDBP genes in patients with amyotrophic lateral sclerosis in central-southern China.2016Scientific reports

打开 PubMed 检索ClinicalTrials.gov

其他疾病

脊髓性肌萎缩症

Spinal muscular atrophy

2021–2025 年中国大陆作者发表的 55 篇脊髓性肌萎缩症 PubMed 英文论文中,这家医院牵头了 2 篇,占 3.6%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

长沙有 2 家医院列在脊髓性肌萎缩症下全国有 51 家医院列在脊髓性肌萎缩症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊髓性肌萎缩症开放试验。

这些数字背后的记录
论文中的科室儿科神经内科
牵头的论文2
  1. Administration practices of and adherence to nusinersen in children with spinal muscular atrophy: a multicenter disease registry study in China.2025BMC pediatrics
  2. Postural Tremor Caused by Hirayama Disease Mimicking Essential Tremor.2024Tremor and other hyperkinetic movements (New York, N.Y.)
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. A Study of the Safety and Preliminary Efficacy of NKG001 in Pediatric Patients With Type 1 or Type 2 Spinal Muscular Atrophy进行中,不再招募NCT07617779研究中心不分期2024-04 启动
  2. Adult Spinal Muscular Atrophy (SMA) China Registry进行中,不再招募NCT05618379研究中心2023-01 启动
  3. Pediatric Spinal Muscular Atrophy (SMA) China Registry进行中,不再招募NCT05042921研究中心2021-11 启动
  4. Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy已完成NCT04089566研究中心III期2020-03 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

法布雷病

Fabry disease

2021–2025 年没有牵头法布雷病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

长沙有 2 家医院列在法布雷病下全国有 85 家医院列在法布雷病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的法布雷病开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Study of the Safety and Biologic Activity of AL01211 in Treatment Naive Males With Classic Fabry Disease状态不明NCT06114329研究中心II期2023-10 启动
  2. A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease已完成NCT04974749研究中心III期2022-05 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

庞贝病

Pompe disease

2021–2025 年没有牵头庞贝病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

长沙有 2 家医院列在庞贝病下全国有 30 家医院列在庞贝病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的庞贝病开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Evaluation of the Safety and Efficacy of Infantile-onset Pompe Disease Gene Therapy Drug进行中,不再招募NCT05793307研究中心I/II期2023-06 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.4%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 222025

长沙有 5 家医院列在杜氏肌营养不良下全国有 116 家医院列在杜氏肌营养不良下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。

这些数字背后的记录
论文中的科室儿科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

长沙有 3 家医院列在白塞病下全国有 149 家医院列在白塞病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

Alport 综合征

Alport syndrome

2021–2025 年没有牵头Alport 综合征的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

长沙有 3 家医院列在Alport 综合征下全国有 60 家医院列在Alport 综合征下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Alport 综合征开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.5%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 2220232024: 0020242025: 112025

长沙有 7 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
    分期
    III期
    开始
    2026-04
    登记号
    NCT07390123

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心Huangshan City、上海、临沂、北京、湛江、芜湖、西安、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肾内科病理/检验科
牵头的论文4
  1. Serum ALCAM is a potential novel non-invasive marker for predicting the progression of IgA nephropathy.2025BMC nephrology
  2. Coexistence of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and IgA nephropathy.2023Immunologic research
  3. C5a enhances Vδ1 T cells recruitment via the CCL2-CCR2 axis in IgA nephropathy.2023International immunopharmacology
  4. A Partial Picture of the Single-Cell Transcriptomics of Human IgA Nephropathy.2021Frontiers in immunology
早期论文(2016–2020 年)11
  1. Fecal microbiota characteristics of Chinese patients with primary IgA nephropathy: a cross-sectional study.2020BMC nephrology
  2. Efficacy of corticosteroids in immunoglobulin A nephropathy with less than 25% crescents.2020Clinical and experimental nephrology
  3. Anaphylatoxins enhance Th9 cell recruitment via the CCL20-CCR6 axis in IgA nephropathy.2020Journal of nephrology
  4. Retrospective Analysis of Clinical Outcomes in Patients with Immunoglobulin A Nephropathy and Persistent Hematuria Following Renin-Angiotensin System Blockade.2020Medical science monitor : international medical journal of experimental and clinical research
  5. Respiratory Syncytial Virus Exacerbates Kidney Damages in IgA Nephropathy Mice via the C5a-C5aR1 Axis Orchestrating Th17 Cell Responses.2019Frontiers in cellular and infection microbiology
  6. Tonsillitis exacerbates renal injury in IgA nephropathy through promoting Th22 cells chemotaxis.2018International urology and nephrology
  7. NLRC5: potential novel non-invasive biomarker for predicting and reflecting the progression of IgA nephritis.2018Journal of translational medicine
  8. Intrinsic renal cells induce lymphocytosis of Th22 cells from IgA nephropathy patients through B7-CTLA-4 and CCL-CCR pathways.2018Molecular and cellular biochemistry
  9. Acteoside relieves mesangial cell injury by regulating Th22 cell chemotaxis and proliferation in IgA nephropathy.2018Renal failure
  10. Losartan and Dexamethasone may inhibit chemotaxis to reduce the infiltration of Th22 cells in IgA nephropathy.2017International immunopharmacology
  11. Identification of a novel collagen type IV alpha-4 (COL4A4) mutation in a Chinese family with autosomal dominant Alport syndrome using exome sequencing.2016The Indian journal of medical research
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN正在招募NCT07390123研究中心III期2026-04 启动
  2. A Study of Telitacicept for IgA Nephropathy (TELIGAN)进行中,不再招募NCT05799287研究中心III期2023-04 启动
  3. Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy状态不明NCT02231125研究中心IV期2014-09 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

成骨不全症

Osteogenesis imperfecta

2021–2025 年中国大陆作者发表的 99 篇成骨不全症 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.0%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

长沙有 4 家医院列在成骨不全症下全国有 59 家医院列在成骨不全症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的成骨不全症开放试验。

这些数字背后的记录
论文中的科室耳鼻喉/头颈外科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年没有牵头原发性胆汁性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头

长沙有 2 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
    分期
    III期
    开始
    2025-12
    登记号
    NCT07282353

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 35 家列出的医院为研究中心Baoji、上海、临沂、北京、十堰、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、天津、成都、杭州、沈阳、深圳、湛江、福州、西安、郑州、重庆、长春、长沙、青岛

  2. 正在招募
    Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis
    分期
    II/III期
    开始
    2023-02
    登记号
    NCT05749822

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:空军军医大学西京医院;另有 11 家列出的医院为研究中心Yan’an、北京、南京、天津、广州、成都、昆明、沈阳、西安、郑州、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室消化/肝病科
中文论文(未计入)1
  1. [Research progress of intestinal-hepatic axis in primary biliary cholangitis].2025Zhonghua nei ke za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA正在招募NCT07282353研究中心III期2025-12 启动
  2. Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis正在招募NCT05749822研究中心II/III期2023-02 启动
  3. CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)进行中,不再招募NCT05896124研究中心II期2023-08 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性硬化性胆管炎

Primary sclerosing cholangitis

2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.0%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

长沙有 2 家医院列在原发性硬化性胆管炎下全国有 90 家医院列在原发性硬化性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。

这些数字背后的记录
牵头的论文1
  1. ANXA1 is identified as a key gene associated with high risk and T cell infiltration in primary sclerosing cholangitis.2023Human genomics
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis)进行中,不再招募NCT05896137研究中心II期2023-08 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

家族性腺瘤性息肉病

Familial adenomatous polyposis

2021–2025 年没有牵头家族性腺瘤性息肉病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

长沙有 3 家医院列在家族性腺瘤性息肉病下全国有 76 家医院列在家族性腺瘤性息肉病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Extensive metabolic disorders are present in APC(min) tumorigenesis mice.2016Molecular and cellular endocrinology

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

中南大学湘雅医院

Xiangya Hospital

长沙

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
Xiangya Hospital of Central South University; Xiangya Hospital Central South University; XiangYa Hospital; Xiangya Hospital of Central South University (H. Yang); Clinical Anatomy Center of Xiangya Hospital; Xiangya Hospital of Centre-south University; General Surgery of Xiangya Hospital

提出更正下载数据